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epithelium belongs to the tissues with the lowest partial pressure of oxygen in the body, and chronic
inflammation is associated with an increased chance to develop colon cancer. How the colonic epithelium
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that was confirmed by coimmunoprecipitation in MC-38 and CT26 colon adenocarcinoma cells and in
situ by proximity ligation assay. Down-regulation of TRAF6 resulted in virtual abrogation of orthotopic
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TRAF6 pathways.
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Abstract 
Hypoxia and inflammation are key factors for colorectal cancer tumorigenesis. The colonic epithelium belongs to the tissues with 
the lowest partial pressure of oxygen in the body, and chronic inflammation is associated with an increased chance to develop colon 
cancer. How the colonic epithelium responds to hypoxia and inflammation during tumorigenesis remains to be elucidated. Here we 
show, that murine colon adenocarcinoma cells with attenuated response to hypoxia, due to a knock-down (KD) of HIF-1 α, produce 
smaller and less hypoxic tumors in an orthotopic mouse model when compared to tumors induced with control cells. HIF-1 α- 
KD tumors showed more functional perfused vasculature associated with increased levels of vessel-stabilizing factors and reduced 
levels of proangiogenic factors, including extracellular matrix protein Cyr61/CCN1. Intratumoral injection of Cyr61 in HIF-1 α- 
KD tumors revealed an in increased vessel permeability and tumor hypoxia. Further bioinformatics analysis identified a possible 
interaction between HIF-1 α and TRAF6, an upstream effector of the NF- κB pathway that was confirmed by coimmunoprecipitation 
in MC-38 and CT26 colon adenocarcinoma cells and in situ by proximity ligation assay. Down-regulation of TRAF6 resulted in 
virtual abrogation of orthotopic tumor growth. Subcutaneous TRAF6-KD tumors were smaller and contained reduced vessel size and 
differently polarized macrophages. These data demonstrate that the tumor cell response to increased hypoxia in the colon leads to 
promotion of nonfunctional angiogenesis, regulated by both hypoxia and TRAF6 pathways. 
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Introduction 
Colorectal cancer is the second and third most frequently occurring 
cancer in women and men, respectively [1] . Hypoxia and inflammation 
promote tumorigenesis and metastasis through modulation of the tumor 
microenvironment. Tumor-promoting inflammation contributes to stromal 
cell polarization supporting angiogenesis [2] . During tumorigenesis, vessels 
are frequently structurally and functionally abnormal and leaky, which results 
in reduced perfusion that contributes to enlargement of hypoxic regions, 
which promote metastasis but also render tumors resistant to chemo- and 
radiotherapy [3] . 
Hypoxia-inducible factor (HIF) is the main regulator of the hypoxic 
response of tumor cells. HIF is a heterodimer constituted by either HIF-1 α
or HIF-2 α and a common HIF-1 β subunit. Under normoxia, the HIF- α
subunits are modified by prolyl hydroxylases and destined for proteosomal 
degradation. Under hypoxia, HIF- α subunits are rapidly stabilized and 
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translocate to the nucleus, where upon heterodimerization bind to hypoxia 
response elements, leading to enhance transcription of several hundred target 
genes [4 , 5] . Hypoxia and other factors associated with pathological stress, 
such as inflammation or cancer, trigger HIF expression, stabilization, and 
activity in immune cells [6] . Tumor cells also directly react to hypoxia through 
HIF-driven responses and modulate tumor microenvironment, angiogenesis, 
and inflammation; thereby promoting tumorigenesis. For instance, HIF- 
1 α expression in glioblastoma tumors is responsible for upregulation of 
chemokines, e.g., CXCL12 that drives bone marrow-derived myeloid cell 
recruitment, contributing to vascular remodeling [7] . In breast cancer cells, 
HIF-1 α stabilization induces the expression of the extracellular matrix 
remodeling enzymes lysyl oxidase and MMPs, leading to a more aggressive 
phenotype and metastasis [8] . However, in colon cancer HIF-1 α and HIF- 
2 α apparently have different roles, regulating cell proliferation and anchor- 
independent growth, respectively [9] . While, the epithelial disruption of 
HIF-2 α significantly decreased neutrophil infiltration in colon cancer [10] , 
HIF-1 α stabilization in proximal colon augments inflammation and cancer 
progression [11] . 
Chronic inflammatory diseases, including inflammatory bowel disease 
and Crohn’s disease, increase the probability of developing colorectal cancer 
[12] . Infiltration of immune cells, such as granulocytes, results in increased 
production of reactive oxygen species that induces genomic instability and 
results in malignant transformation and inflammatory activation of epithelial 
cells [13] . The nuclear factor NF- κB is the central transcription factor 
activated by a variety of inflammatory factors derived from either tumor 
cells or a tumor microenvironment during malignant progression [14] . The 
expression of tumor promoting cytokines, such as IL-6 or TNF- α, and 
antiapoptosis survival genes are dependent on NF- κB, thus making it a 
critical factor in cancer progression [14 , 15] . Altered NF- κB activation has 
been detected in many solid tumors where it regulates the expression of genes 
affecting proliferation, migration, and apoptosis [14 , 16] . Tumor initiation in 
colorectal cancer is dependent on an intact IKK β-mediated NF- κB signaling 
[17] . However, the impact of upstream NF- κB mediators such as IKK in 
colon cancer remains to be defined. 
Microbial oxygen consumption and large oxygen diffusion distances lead 
to an anoxic environment in the lumen of the colon [18] . Therefore, hypoxia 
is likely a main modulator of cancer progression in the colon epithelium, 
which together with the omnipresent inflammatory stimuli derived from 
microbiota promotes tumor inflammation. Previously, we have shown that 
MC-38 cells express only the HIF-1 α subunit, which is the sole driver of 
hypoxic responses in this cell line [19] . Here we tested the role of HIF-1 α in 
tumor cells on colorectal tumor development in an orthotopic mouse model 
using MC-38 mouse adenocarcinoma cells, where the stromal compartment 
has normal HIF-1 α activity. Bioinformatics approaches identified a direct 
interaction between hypoxic and inflammatory signaling pathways required 
for tumor progression. 
Materials and methods 
Cell culture 
Mouse colon adenocarcinoma cells expressing GFP (MC-38GFP) and 
CT26 cells were cultured in high glucose DMEM (Sigma) supplemented 
with 10%FBS, NEAA and 1 mmol/L Na-pyruvate (all Gibco). Cells exposed 
to hypoxia were grown in a gas-controlled workstation (InvivO 2 400, 
Baker-Ruskinn Technologies). MC-38-HIF-1 α-KD cells were prepared as 
previously described [19] . MC-38-TRAF6-KD was prepared by lentiviral 
transduction of shRNA vectors in pLKO.1-puro plasmid (Sigma). shRNA 
constructs targeting mouse TRAF6 and nontarget controls (Mock) were 
purchased from Sigma. 
Mice 
All animal experiments were performed according to the guidelines of 
the Swiss Animal Protection Law and approved by the Veterinary Office of 
the Kanton Zurich. C57BL/6 J mice were purchased from Charles River, 
Germany. 
Mouse tumor models 
Orthotopic colon tumor model: mice were anesthetized by intraperitoneal 
injection of ketamine/xylaxine/acepromazine (65/10/2 mg/kg per mouse) in 
saline buffer. After shaving of the abdominal part, a small incision (2–3 mm) 
was performed and the cecum was exposed. Using a 27 G needle, 40,000 
tumor cells in growth factor-reduced Matrigel (Corning) were injected in 
the cecum wall and both peritoneal and skin layers were subsequently 
stitched. For analgesia, mice were subcutaneously injected with Meloxicam, 
5 mg/kg (Boehringer Ingelheim) 30 min prior- and 6 h and 24 h postsurgery. 
Subcutaneous tumor model: mice were injected in the right flank with 
500,000 MC-38GFP Mock or TRAF6-KD cells. Tumor size was measured 
with caliper every day and mice were sacrificed at day 19 after injection or 
when the tumor volume reached 1 cm 3 . 
Flow cytometry analysis of tumors 
Mice were perfused with phosphate buffer saline (PBS) through the left 
ventricle and dissected orthotopic tumors were digested with collagenase IV, 
hyaluronidase and DNAse I (all Sigma) in 2% fetal bovine serum/RPMI 
(FBS/RPMI) for 1 h at 37 °C. The cell suspension was filtered through a 100- 
μm cell strainer, erythrocytes lysed, and filtered through a 40-μm cell strainer 
(BD). Cells were stained with Zombie Fixable Viability Kit (Biolegend) 
and incubated with anti-CD16/32 for 10 min in FACS buffer (PBS/10 
mmol/L EDTA, 2% FCS), followed by incubation with antibodies: anti- 
CD45 (clone 30-F11), anti-CD11b (clone M1/70), anti-Ly6G (clone 1A8), 
anti-Ly6C (clone HK1.4); all from Biolegend. In case of subcutaneous tumors 
the following antibodies were used in addition: anti-CD11c (clone N418), 
anti-CD64 (clone X54–5/7.1), anti-CD103 (clone 2E7), anti-MHCII (clone 
M5/114.15.2), anti-CD206 (clone C068C2) and anti-VCAM1 (clone 429); 
all from Biolegend. Data were acquired with a LSR II Fortessa cytometer 
(BD) and analyzed by FlowJo software v. 7.6.5 (TreeStar). 
Hypoxia staining and angiogenic analysis of tumors 
Mice were i.v. injected with 1.5 mg pimonidazole (Hypoxyprobe) one 
hour before termination. For determination of tissue perfusion, mice were i.v. 
injected with 100 μg FITC-labeled Lycopersicon esculentum (tomato) lectin 
(Vector Labs) 5 min prior to whole body perfusion with PBS followed by 
tumor dissection and embedding in OCT (TissueTek). Tissue sections (5 
μm) were fixed for 10 min in ice-cold acetone, rehydrated in PBS and 
blocked with 1%BSA in PBST (PBS/0.1% Tween 20) for one hour at room 
temperature (RT). Sections were then incubated with anti-pimonidazole 
(Omni Kit Hypoxyprobe) and anti-CD31 (Biolegend) antibodies overnight 
at 4 °C in blocking buffer. After washing with PBST (3 ×), antibodies: 
anti-rabbit-AF568, anti-rat-AF647 (Life Technologies) were incubated for 
1 h at RT, counterstained with DAPI (Sigma) and mounted in Prolong 
Gold (Life Technologies). Pericytes were stained with anti-NG2 (Millipore). 
Pimonidazole, CD31 or NG2 staining was determined using MIRAX MIDI 
Slide Scanner (Zeiss). Images were acquired with a CLSM SP5 Resonant 
APD Confocal Microscope (Leica) and analyzed with the Imaris software 
(Bitplane). Vessel area was calculated using the software Pannoramic Viewer 
1.15.2 (3D Histech). 
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Vascular permeability assay 
Mice with orthotopic tumors were intratumorally injected with 
recombinant Cyr61 (400 ng, Cusabio Biotech) reconstituted in HBSS every 
other day starting on day 21 after tumor cell injection (3 × in total). Prior 
to termination, mice were injected with pimonidazole (as described above) 
followed by i.v. injection of Evans Blue (2 mg) and terminated 30 min later; 
dissected tumors were embedded in OCT. Staining of pimonidazole and 
CD31 was performed as described above. Evans Blue staining was analyzed 
using optimal excitation and emission filters at 620 and 680 nm, respectively. 
Cytokine analysis 
Cytokines and chemokines in tumor lysates were analyzed using 
ProcartaPlex Mouse Panel 1 (26-plex; eBioscience) using a Bio-Plex System 
(Biorad) with xMAP Luminex technology. Protein concentration was 
determined using the BCA assay following the manufacturer’s instructions 
(Thermo Fisher). 
Gene expression in sorted cells 
Cell suspension (described above) was stained with Zombie Fixable 
Viability Kit followed by incubation with anti-CD16/32 and staining with 
anti-CD45 (clone 30-F11) and anti-CD31 (clone 390); all from Biolegend. 
At least 50,000 tumor cells (CD45 neg ,CD31 neg ,GFP + ) were sorted per 
sample. RNA was extracted using RNeasy Plus Mini Kit (Qiagen) and cDNA 
was synthesized using Omniscript RT Kit (Qiagen). qPCR was performed 
with KAPA SYBR FAST quantitative PCR (qPCR) Master Mix (KAPA 
Biosystems) and analyzed in a CFX96 Touch Real-Time PCR Detection 
System (Biorad). 
RNA library preparation 
The quantity and the quality of the isolated RNA was determined with 
a Qubit (1.0) Fluorometer (Life Technologies) and a Bioanalyzer 2100 
(Agilent). The TruSeq Stranded mRNA Sample Prep Kit (Illumina) was used 
in the next steps. Briefly, total RNA samples (100 ng) were poly-A selected 
and then reverse-transcribed into double-stranded cDNA with Actinomycin 
D added during first-strand synthesis. The cDNA samples were fragmented, 
end-repaired and adenylated before ligation of TruSeq adapters. The adapters 
contain the index for multiplexing. Fragments containing TruSeq adapters on 
both ends were selectively enriched with PCR. The quality and quantity of 
the enriched libraries were validated using Qubit (1.0) Fluorometer and the 
Bioanalyzer 2100. 
Cluster generation and sequencing 
The TruSeq SR Cluster Kit v4-cBot-HS (Illumina) was used for cluster 
generation using 8 pM of pooled normalized libraries on the cBOT. 
Sequencing were performed on the Illumina HiSeq 4000 single end 125 bp 
using the TruSeq SBS Kit v4-HS (Illumina). 
RNA sequencing data analysis 
Bioinformatics analysis of RNA sequencing data was performed with 
SUSHI software [20] . In detail, the raw reads were quality checked 
using Fastqc ( http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ ) 
and FastQ Screen ( http://www.bioinformatics.babraham.ac.uk/projects/ 
fastq _ screen/ ). Quality controlled reads (adaptor trimmed, first 5 and last 
6 bases hard trimmed, minimum average quality Q10, minimum tail quality 
Q10, minimum read length 20 nt) were aligned to the reference genome 
(Ensembl GRCh38, not patched) using STAR aligner [21] . Read alignments 
were only reported for reads with less than 50 valid alignments. Expression 
counts were computed using feature Counts in the Bioconductor package 
Subread [22] . Differential expression was computed using the DESeq2 
package [23] . The RNAseq data have been deposited in gene expression 
omnibus database under the accession number (GSE155104). 
Protein-interaction network analysis 
Differently expressed genes from MC-38 cells cultivated under hypoxia 
and normoxia were used for further analyses: mouse I2D ver. 2.3 ( http: 
//ophid.utoronto.ca/i2d ) was used to identify their interacting partners 
[24] . Resulting network was annotated, analyzed and visualized using 
NAViGaTOR 3.013 [25] . Gene Ontology enrichment analysis was 
performed using clusterProfiler_3.16.0 [26] on mouse genome wide 
annotation (org.Mm.eg.db 3.11.4). Enrichment was performed on Biological 
Process – BP and Cellular Component – CC. Top 20 terms from each of 
the ontology were plotted. Mouse gene symbols were converted to human 
gene symbols using biomaRt 2.44.0 [27] , and 568 mouse gene symbols were 
converted to 526 human gene symbols. Disease enrichment analysis was 
performed on the list of human gene symbols with DOSE_3.14.0 [28] using 
DisGeNet (DGN). Plots were obtained using clusterProfiler. All analyses were 
performed using R 4.0.0. ( https://www.r-project.org/ ). 
Immunoprecipitation 
MC-38 Mock, HIF-1 α-KD and TRAF6-KD cells were cultured under 
hypoxia (0.2% O 2 ) for 8 hours with or without LPS stimulation (1 μg/mL) 
for 1 h at 37 °C. Cells were resuspended in lysis buffer (10 mM Tris- 
HCl pH 8.0, 1 mM EDTA, 400 mM NaCl, 0.1% NP-40) and Sigma’s 
Protease Inhibitor Cocktail. Total protein amount was determined using 
the BCA assay. Total lysate (1.5 mg) was incubated with 6 μg anti-TRAF6 
(Clone: d -10, Santa Cruz) or anti-HIF-1 α antibody (Clone: H1 α67, Santa 
Cruz) and 40 μL Dynabead Protein G (ThermoFisher) slurry overnight 
at 4 °C. Beads were washed with PBS (3 ×), boiled in Laemmli buffer 
at 95 °C for 5 min. The supernatant was separated by 10% SDS-PAGE, 
transferred to a nitrocellulose membrane, and incubated with anti-HIF- 
1 α (rabbit polyclonal, Novus Biologicals) or anti-TRAF6 (Clone: EP591Y, 
Abcam) antibodies, respectively. 
Immunohistochemistry 
Tissue paraffin sections (5 μm) were stained with hematoxylin/eosin or 
the following antibodies: Ki67 (NeoMarkers), and cleaved caspase-3 (Cell 
Signaling). Staining was performed on a NEXES immune-histochemistry 
robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana 
Instruments) or on a Bond MAX (Leica). Images were digitized with a Axio 
Scan.Z1 slide scanner (Zeiss) and analyzed using Zen Blue image analysis 
software (Zeiss) and Fiji (ImageJ). Tissue sections were stained simultaneously 
for each antigen and the signal-to-noise cutoff was manually adjusted for 
each antibody staining and applied to all samples within one staining 
group. 
Proximity ligation assay 
MC-38 cells were cultured on coverslips (12 mm diameter) under 
normoxia (21% O 2 ) or hypoxia (0.2% O 2 ) for 8 h. Cells were washed with 
1 × PBS and fixed with 4% paraformaldehyde (PFA) for 15 min at room 
temperature. Samples were washed twice with 1 × PBS and permeabilized 
with 0.1% Tween-20 in 1 × PBS for 10 min at room temperature. Duolink 
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In Situ Orange Starter Kit Mouse/Rabbit (Sigma) was used together with a 
mouse-anti HIF1 α (Clone: H1alpha67, Novus Biologicals) and rabbit-anti 
TRAF6 (ab33915, Abcam) antibodies were used at 20 μg/mL. Blocking and 
staining was performed following manufacturer’s recommendations. 
Statistical analysis 
Statistical analysis was performed with the GraphPad Prism software 
(version 6.03). All data are presented as mean ±SEM and were analyzed by 
ANOVA with the post-hoc Bonferroni multiple comparison test. Analysis of 
2 groups was performed with Mann-Whitney test unless stated otherwise. 
Results 
Impaired hypoxic response in colorectal tumor cells results in smaller 
orthotopic tumors 
To test how impaired responsiveness of tumor cells to hypoxia affects 
tumorigenesis, we tested the growth of mouse colon carcinoma cells (MC- 
38) with stable down-regulation of HIF-1 α (HIF-1 α-KD) in an orthotopic 
model. We previously showed that the hypoxic response in MC-38 cells 
is solely dependent on HIF-1 α [19] . We confirmed that MC-38 HIF- 
1 α-KD cells have reduced HIF-1 α mRNA levels and minimally respond 
to hypoxia (Supplementary Figure 1). Intracecal injection of HIF-1 α-KD 
cell resulted in reduced tumor growth when compared to control MC- 
38 (Mock) cells ( Figure 1 A). Since hypoxia had previously been shown to 
attenuate inflammatory responses in MC-38 cells in vitro [19] , we analyzed 
the composition of the immune cells in the tumor microenvironment by flow 
cytometry. Analysis of tumor infiltrating cells revealed a reduced number 
of granulocytes (Ly6G + cells), but increased presence of inflammatory 
monocytes (Ly6C + cells) in HIF-1 α-KD tumors, when compared to Mock 
tumors ( Figure 1 B). We observed no major changes in the number of 
macrophages; CD64 + CD11c −; or tumor-associated macrophages; TAMs 
- CD64 + CD11c + ; (Supplementary Figure 1D-E). Neither there were any 
significant changes in polarization of macrophages or TAMs. Histological 
analysis of tumors showed a reduced presence of Ly6G + cells. However, no 
changes in numbers of myeloid cells (CD11b + Ly6C −Ly6G lo ) were observed 
( Figure 1 B). To understand the changes in tumor infiltration of innate 
immune cells caused by reduced HIF-1 α activity, we analyzed the levels 
of cytokines in tumor homogenates ( Figure 1 C). Increased levels of CCL2 
and CCL7 were detected in HIF-1 α-KD tumors, which correlated with the 
enhanced presence of inflammatory monocytes ( Figure 1 D). 
HIF-1 α-KD tumors are less hypoxic and contain more functional vessels 
To assess whether the reduced hypoxia response in tumor cells alters 
hypoxia in HIF-1 α-KD tumors, we injected pimonidazole, which forms 
covalent adducts if the oxygen partial pressure falls below approximately 10 
mm Hg. Significant reduction of the hypoxic region was detected in HIF- 
1 α-KD tumors when compared to Mock tumors of similar size ( Figure 2 A). 
Next, we analyzed the tumor vasculature and determined the size of blood 
vessels (vessel area) that allows assessment of angiogenesis. We observed larger 
vessel areas (CD31 + ) in hypoxic (pimonidazole + ) regions when compared 
to nonhypoxic (pimonidazole −) regions, which was independent of HIF 
expression by tumor cells ( Figure 2 B). This observation is in agreement with 
the well-known effect of hypoxia on induction of vessel formation [29] . 
However, HIF-1 α-KD tumors showed a reduced intra-tumoral total number 
of vessels when compared to Mock tumors ( Figure 2 C), indicating changes 
in angiogenesis. When we analyzed the vessel maturation by detection of 
pericytes, using anti-NG2 Ab, a significantly increased number of immature, 
NG2-negative vessels were detected in Mock tumors when compared to HIF- 
1 α-KD tumors ( Figure 2 C). The vessel functionality was determined with 
tomato lectin-FITC perfusion of tumor-bearing mice ( Figure 2 D). HIF- 
1 α-KD tumors showed more perfused, tomato lectin-positive, vessels. The 
number of perfused vessel was higher in HIF-1 α-KD tumors irrespective of 
hypoxic and nonhypoxic tumor regions. The correlation between the degree 
of vessel perfusion and the pimonidazole staining confirmed the increased 
perfusion in HIF-1 α-KD tumors ( Figure 2 E). To determine how the 
reduced responsiveness of tumor cells to hypoxia affects tumor angiogenesis, 
we analyzed tumor lysates using an angiogenesis protein antibody array 
(Supplementary Figure 2). The analysis of 53 different proteins showed higher 
amounts of proangiogenic factors (e.g., angiopoetin-1, Cyr61) in Mock 
tumors when compared to HIF-1 α-KD tumors. These data indicate that 
the impaired hypoxia response in HIF-1 α-KD colorectal tumors is associated 
with reduced vessel formation. 
Alterations of inflammatory and angiogenic genes in orthotopic 
HIF-1 α-KD tumors 
To understand the role of HIF-1 α on tumor growth, we sorted MC- 
38GFP tumor cells from orthotopic HIF-1 α-KD and Mock tumors and 
analyzed the transcriptome using RNA sequencing. In HIF-1 α-KD tumor 
cells we found 280 genes significantly upregulated ( P < 0.05), while 288 genes 
were downregulated when compared to Mock tumor cells ( Figure 3 A, Table 
S1). 
Gene ontology enrichment analysis using clusterProfiler_3.16.0 on mouse 
genome wide annotation revealed an upregulation of genes involved in 
biological processes and cellular components ( Figure 3 B). Specifically, 
regulation of vasculature development and angiogenesis together with cell 
chemotaxis were increased in HIF-1 α-KD tumor cells when compared 
to Mock tumor cells. Simultaneously, cellular components of extracellular 
matrix and basement membrane genes were increased. The disease 
enrichment analysis of identified genes in DisGeNET (a curated human 
dataset of gene-disease association [30] confirmed the tumor angiogenesis as 
one of the significantly upregulated pathways (Supplementary Figure 3)). To 
understand the observed changes in leukocyte infiltration and angiogenesis, 
we focused on genes involved in these processes. Several genes involved 
in angiogenesis and vessel maturation, including endostatin gene Col18a1, 
Pdgfa Peli1 Angptl4 and Cyr61 , were found to be differentially regulated 
( Figure 3 C). Interestingly, factors contributing to blood vessel stabilization, 
such as endostatin derived from collagen XVIII and Pdgfa , were upregulated 
in HIF-1 α-KD tumor cells. 
Endostatin production depends on the proteolytic cleavage of collagen 
XVIII by matrix metalloproteinases [31] . Indeed, higher MMP9 expression 
was detected in lysates of HIF-1 α-KD tumors (Supplementary Figure 2), 
which is in agreement with observed reduced number of blood vessels 
( Figure 2 C). In addition, factors inducing inflammatory responses, like 
Peli1, Pgts2, Socs3, and Tnfrsf9 , were downregulated, while an inhibitor of 
the NF- κB pathway ( Nfkbie ) was upregulated in HIF-1 α-KD tumor cells. 
Validation of several identified mRNA species by real-time qPCR confirmed 
the downregulation of the proangiogenic Cyr61 and Pgts2 as well as the 
proinflammatory Cox2 and Tnfrsf9 transcripts and the upregulation of a 
vessel-stabilizing factor Pdgfa in HIF-1 α-KD tumor cells ( Figure 3 D). Of 
note, expression of carbonic anhydrase 9, a typical marker of hypoxia, was 
also reduced in HIF-1 α-KD tumor cells. These data show that the hypoxic 
response in tumor cells directly induces the release of factors modulating 
inflammation and angiogenesis within the tumor microenvironment. 
Since HIF-1 α expression in colorectal cancer correlates with poor 
prognosis [32 , 33] , we examined human colorectal tumor samples in 
the Medisapiens database ( http://ist.medisapiens.com/ ) for the expression 
of HIF-1 α and transcripts identified to be dysregulated in HIF-1 α- 
KD tumor cells. The analysis of 991 patients dataset showed a direct 
correlation between HIF-1A mRNA levels and LOX, CYR61, PGTS2, 
SOCS3, TIMP3, PELI1, TNFRSF9, and ANGPTL4 (Supplementary 
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Figure 1. MC-38 colorectal tumor cells with reduced HIF-1 α transcript levels lead to reduced orthotopic tumor growth associated with changes in tumor 
microenvironment. (A) Weight of tumors 28 days after intracecal injection of HIF-1 α-KD and control (Mock) MC-38 cells (left panel). Representative 
images of H&E stained tumors from respective tumors (right panel). Scale bar = 1 mm. (B) Flow cytometry analysis of immune cells in tumors: 
CD11b + /Ly6C −/Ly6G lo myeloid cells (left panel); Ly6G + granulocytes (middle panel), Ly6C hi /Ly6G lo inflammatory monocytes (right panel) presented 
as percentage of total living CD45 + cells. Representative images of orthotopic tumors stained with Ly6G-antibody (red) and counterstained with DAPI. 
Bar = 30 μm. (C) Amounts of cytokines detected in tumor homogenates at day 28. (D) Amounts of Ccl2 and Ccl7 chemokines in tumor homogenates. 
Statistical significance was assessed using the Mann-Whitney test; ∗, P < 0.05; ∗∗, P < 0.01. (Color version of figure is available online.) 
Figure 4A), which is in agreement with data obtained from the MC-38 
mouse model. Similarly, the analysis using 594 colorectal cancer patient 
samples from Colorectal Adenocarcinoma dataset (TCGA, PanCancer Atlas; 
https://www.cbioportal.org/ ver. 3.4.3) confirmed the significant correlation 
between HIF-1 α and the genes identified in MC-38 model (Supplementary 
Figure 4B). 
Intratumoral delivery of CYR61 increases tumor hypoxia and vascular 
permeability in HIF-1 α-KD tumors 
Pathologic tumor neovascularization and aggressiveness have been 
linked to the expression of Cyr61/CCN1 in breast and pancreatic 
cancer cells [34–36] . Cyr61 is an extracellular matrix protein promoting 
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Figure 2. Impaired HIF-1 α signaling in MC-38 tumor cells results in vascular normalization in tumors. (A) Quantification of hypoxic regions in tumors as 
percentage of pimonidazole positive area over total tumor area in Mock and HIF-1 α-KD tumors. Representative images of hypoxic regions in cecum tumors 
visualized by pimonidazole staining, red; counterstained with DAPI, blue (lower panel). Scale bar = 1 mm (overview); scale bar = 500 μm (enlarged) panels. (B) 
Total vessel area in pimonidazole positive and negative regions of orthotopic tumors determined by counting of CD31-positive vessels. Comparison of Mock 
and HIF-1 α-KD tumors from 3 independent experiments. (C) Total number of vessels (CD31 + ) per view field (PVF) in Mock and HIF-1 α-KD tumors (left 
panel) and immature vessels as determined by NG2-staining of pericytes; NG2 −CD31 + ; (right panel). Representative immunofluorescence images of tumors 
stained for NG2 (green), CD31 (red) and DAPI (blue). Three random view fields were counted per tumor, n = 4–5 mice per group. Scale bar = 200 μm. (D) 
Representative images of vessels perfused with tomato lectin (TL; green) in pimonidazole positive (white) and pimonidazole negative tumors regions. Vessels 
were stained with CD31 Ab (red) and counter-stained with DAPI (blue). Scale bar = 50 μm. Ratio of perfused vessels (TL + /CD31 + ) over total number of 
vessels (CD31 + ) per view field, assessed in both pimonidazole positive and negative regions (right panel). Three random view fields were analyzed per tumor, 
n = 3 per mouse group. Mice from 3 independent experiments were analyzed at day 28 post-tumor cell injection in panels A-C. (E) Correlation analysis 
between the degree of tumor perfusion and tumor hypoxia (pimonidazole-positive areas) in Mock and HIF-1 α-KD tumors, respectively from histological 
sections shown in panel D. Statistical significance was assessed using the Mann-Whitney test; ∗, P < 0.05; ∗∗, P < 0.01. (Color version of figure is available 
online.) 
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Figure 3. Upregulation of vessel-stabilizing factors and downregulation of proangiogenic molecules in HIF-1 α-KD orthotopic tumors. (A) RNA sequencing 
results from Mock and HIF-KD sorted tumor cells from orthotopic tumors ( > 50,000 cells) presented as a heatmap. (B) Gene Ontology enrichment analysis 
performed on genes that were significantly deregulated in sorted HIF-1 α-KD when compared to Mock tumor cells. (C) Fourteen genes linked to angiogenesis 
and inflammation which are differently regulated between HIF-1 α-KD and Mock tumor cells. Statistically significant differences: at least P < 0.01. (D) 
Expression levels of selected differentially regulated genes in HIF-1 α-KD and Mock tumor cells, normalized to ribosomal protein S12 mRNA, were validated 
by qPCR ( n = 4–5). Statistical significance was assessed with Mann-Whitney test; ∗, P < 0.05; ∗∗, P < 0.01. 
endothelial cell proliferation, adhesion, and differentiation [37] . We observed 
downregulation of Cyr61 in HIF-1 α-KD tumor cells ( Figure 3 C-D) as well 
as in tumors (Supplementary Figure 2). To test whether Cyr61 affects the 
tumor growth of colon carcinoma, we intratumorally injected recombinant 
Cyr61 into HIF-1 α-KD tumors. Increased hypoxic regions, determined by 
pimonidazole staining, were observed upon Cyr61 injection when compared 
to control tumors treated with the solvent HBSS ( Figure 4 A). No changes 
in vessel density were observed between Cyr61 and control tumors in 
the hypoxic regions while a significant reduction of vessel numbers was 
observed in pimonidazole-negative regions ( Figure 4 B). However, Cyr61 
injection induced larger vessels, as determined by the vessel area, which 
correlated with reduced vessel density in pimonidazole-negative regions. To 
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Figure 4. Intratumoral treatment of HIF-1 α-KD orthotopic tumors with Cyr61 protein increases tumor hypoxia and vascular leakiness. (A) Representative 
images of hypoxic regions in HIF-1 α-KD tumors treated with Cyr61 or HBSS (control) visualized by pimonidazole staining (green) and counterstained with 
DAPI (blue). Quantification of hypoxic regions as percentage of pimonidazole positive area over total tumor area in respective tumors (lower panel); n = 6–8 
tumors per group. (B) Representative images of blood vessels (CD31 staining, red) in HIF-1 α-KD tumors either treated with Cyr61 or HBSS. Hypoxic and 
non-hypoxic regions visualized by pimonidazole (green) and counterstained with DAPI (blue) for respective treatments. Lower panels show total vessel area 
(CD31 + ) and the average vessel density per view field (PVF), determined in randomly chosen 2 view fields per tumor sample ( n = 4–5 tumors per group). 
(C) Representative images of Evans Blue staining (white) in HIF-1 α-KD tumors treated with either Cyr61 or HBSS. Quantification of vascular permeability 
in tumors shown as a percentage of Evans Blue positive area over total tumor area ( n = 5–8 tumors per group). Statistical significance was assessed using the 
Mann-Whitney test; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001. (Color version of figure is available online.) 
test whether Cyr61 injection affected the functionality of vessels, we injected 
Evans Blue and assessed extravasation of the dye ( Figure 4 C). HIF-1 α- 
KD tumors injected with recombinant Cyr61 showed increased vascular 
permeability, which is in agreement with Cyr61 as an inducer of aberrant 
tumor angiogenesis associated with nonfunctional leaky vessels and hypoxia. 
HIF-1 α interacts with TRAF6 upstream of NF- κb in MC-38 cells 
Inflammation is directly linked to colon cancer development [12] and 
the colonic epithelium is known to be in a physiologically hypoxic state 
[18] . This unique physiological situation in the colon stimulated us to 
assess the cross talk between inflammation and hypoxia in the mouse colon- 
cancer model. Previously, we had shown that HIF-1 α levels in MC-38 cells 
remain unchanged upon LPS stimulation, while hypoxia treatment failed to 
induce NF- κB signaling in vitro [19] . We used this dataset of differently 
expressed genes from MC-38 cells for an in silico analysis based on the 
known proteome-wide physical protein-protein interactions ( Figure 5 A). Of 
note, the HIF target and hypoxic tumor hallmark gene carbonic anhydrase 
9 (CA9) was identified among the upregulated genes, which confirms the 
hypoxic culture conditions. Among the identified sixty proteins, the tumor 
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Figure 5. HIF-1 α interacts with TRAF6 and links hypoxia to inflammation in colorectal cancer. (A) Protein-protein interaction network based on differently 
regulated genes observed in MC-38 cells cultured under either hypoxia or normoxia using the NAViGaTOR software. Node size is proportional to the 
expression level in hypoxia versus normoxia. Red lines represent direct interactions among proteins upregulated during hypoxia. Blue, turquoise, and green 
lines show indirect/mediated interactions of the TRAF6 with other hypoxia upregulated proteins. (B) Coimmunoprecipitation of TRAF6 and HIF-1 α in 
Mock and HIF-1 α-KD MC-38 cells stimulated either by hypoxia/normoxia with or without addition of LPS followed by the detection of TRAF6 or HIF-1 α, 
respectively (n = 3). (C) Co-immunoprecipitation of TRAF6 and HIF-1 α in CT26 cells stimulated either by hypoxia/normoxia or LPS addition, followed by 
the detection of TRAF6 or HIF-1 α, ( n = 3). (D) Proximity ligation assay in MC-38 Mock cells cultured under normoxia and hypoxia for 8 h followed by 
detection with HIF-1 α and TRAF6-specific antibodies using Duolink In Situ Orange Kit (Sigma). Negative control (No primary Ab) is shown; scale bar = 
15 μm. (Color version of figure is available online.) 
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necrosis factor receptor-associated factor 6 (TRAF6) protein was identified 
as a possible key interaction point with the highest centrality value between 
the hypoxic and inflammatory pathways ( Figure 5 A). Previously, TRAF6 
overexpression in tumor cells had been shown to stabilize HIF-1 α [38] . 
Thus, we tested the hypothesis that TRAF6 directly interacts with HIF-1 α, 
as suggested from the protein-protein interaction network analysis. HIF-1 α- 
KD and Mock MC-38 cells were cultured under normoxia and hypoxia, 
with or without LPS stimulation, followed by TRAF-6 immunoprecipitation 
and HIF-1 α detection ( Figure 5 B). Increased co-immunoprecipitated HIF- 
1 α protein amounts were detected in Mock cells under hypoxia when 
compared to normoxia, indicating physical interaction between TRAF6 and 
HIF-1 α. When HIF-1 α was immunoprecipitated in MC-38 cells stimulated 
with hypoxia, TRAF6 protein was detected (Supplementary Figure 5). LPS 
stimulation alone had no effect on HIF-1 α expression ( Figure 5 B), which 
is in agreement with our previous data [19] . To demonstrate that the HIF- 
1 α-TRAF6 interaction is not cell type specific, coimmunoprecipitation was 
confirmed in murine CT26 colon carcinoma cells ( Figure 5 C). Next, we 
confirmed the TRAF6-HIF-1 α interaction using proximity ligation assay in 
situ. MC-38 Mock cells under normoxia showed interaction between TRAF6 
and HIF-1 α in the cytoplasm, which was increased in cells cultured under 
hypoxia ( Figure 5 D). 
TRAF6 is required for orthotopic tumor growth 
To test the involvement of TRAF6 in tumorigenesis, we prepared MC- 
38GFP with shRNA-induced downregulated TRAF6 expression, MC-38- 
TRAF6-KD (Supplementary Figure 6A-C), and injected them into the cecum 
wall. Interestingly, only three out of twenty one animals developed a very 
small tumor upon MC-38-TRAF6-KD tumor cells injection while all Mock 
cell injections led to tumor formation ( Figure 6 A). To exclude that TRAF6- 
KD tumor cells have a general problem to proliferate in vivo, we intravenously 
injected these cells and followed metastasis to the lungs. Lung tumors grew in 
all mice injected with MC-38-TRAF6-KD cells at similar size as with Mock 
cells, albeit in reduced numbers (Supplementary Figure 6D). Subcutaneous 
injection of MC-38-TRAF6-KD tumor cells also resulted in normal tumor 
development, albeit the size of tumors was reduced when compared to Mock 
tumors ( Figure 6 B). These data indicate that TRAF6 in colorectal tumor cells 
is essential for tumor growth specifically in the colon/cecum. 
Next, we analyzed the composition of TRAF6-KD and Mock 
subcutaneous tumors. TRAF6-KD tumors showed an increased detection 
of apoptotic cells, as determined by cleaved-caspase 3 staining, when 
compared to Mock tumors, which correlates with reduced tumor size 
( Figure 6 C). Interestingly, TRAF6-KD tumor showed also increased number 
of Ki67-positive tumor cells. No major changes in macrophages between 
TRAF6-KD and Mock tumors were observed using immunohistochemistry 
( Figure 6 D). Flow cytometry analysis of tumor infiltrating leukocytes 
revealed an increased presence of inflammatory monocytes (Ly6C hi ), 
and reduced numbers of myeloid cells (CD11b + ) and tumor-associated 
macrophages; TAMs (CD11b + CD64 + CD11c + ) in TRAF6-KD tumors 
( Figure 6 D). The number of macrophages (CD64 + CD11c −) remained 
unchanged between TRAF6-KD and Mock tumors. When we analyzed the 
polarization of macrophages into protumorigenic M2 or antitumorigenic 
M1 one using the CD206 and MHCII markers, respectively, increased 
numbers of M1 type macrophages in TRAF6-KD were observed 
( Figure 6 E), which is in agreement with the observed tumor size reduction 
( Figure 6 B). 
TRAF6-KD tumors show reduced vessel density 
TRAF6 had previously been shown to modulate HIF-1 α expression 
in colonic and breast cancer tumor cells [38 , 39] , and here we showed 
that TRAF6 interacts with HIF-1 α in murine MC-38 and CT-26 
cells. Thus, we asked whether TRAF6-KD affected tumor angiogenesis. 
While the number of vessels was not affected in TRAF6-KD tumors, 
a significantly reduced vessel area, reflecting reduced angiogenesis, was 
observed when compared to Mock tumors ( Figure 6 F). These results 
indicate that that functional TRAF6 signaling contributes to formation 
of aberrant blood vessels in the tumors, reflected in significantly larger 
vessels. 
Discussion 
Inflammation and hypoxia modulate the tumor microenvironment to 
promote tumor progression and invasiveness [40] . Low oxygen tensions, 
present at both inflammatory sites and tumors, stabilize HIF- αs, which 
activates target genes involved in angiogenesis, cell survival, metabolic 
reprogramming, and metastasis. Overexpression of HIF-1 α was observed in 
various human cancers, including colorectal cancer [41] and is independently 
associated with poor prognosis [32] . HIF-1 α is a transcription factor 
regulating tumor cell survival and proliferation; and epithelial barrier 
function following inflammation in the colon [11 , 42 , 43] . Here we 
studied the role of HIF-1 α-mediated response towards hypoxia in an 
orthotopic colorectal cancer model in immunocompetent mice. Importantly, 
we observed smaller HIF-1 α-KD tumors, with reduced infiltration by 
granulocytes. The almost complete absence of a hypoxic response in MC-38 
cells resulted in tumors with less but more functionally perfused vasculature. 
The number and the size of blood vessels in Mock tumors correlated with 
increased tumor hypoxia indicating an active role of tumor cell-derived 
HIF-1 α signaling leading to aberrant, non-functional angiogenesis [3] . In 
this context, down-regulation of HIF-1 α in tumor cells resulted in vessel 
normalization and maturation, and consequently less hypoxia. Of note, 
increased local oxygen consumption by infiltrating granulocytes with active 
respiratory burst contributes to intestinal tissue hypoxia in colitis models 
[44] . Indeed, we observed higher numbers of granulocytes in Mock tumors. 
Recently, metabolic targeting of HIF-1 α has been shown to potentiate 
chemotherapy responses in human colorectal cancer tumor growth in a 
murine model, which was associated with reduced angiogenesis [45] . These 
findings are in agreement with our data showing that MC-38 tumors 
with reduced HIF-1 α expression are smaller, with functional vessels and 
reduced hypoxia. In addition, better-perfused vasculature may explain the 
increased responsiveness to chemotherapy observed previously [45] . Recent 
study provided evidence for microRNA regulated switch between endothelial 
cell proliferation and migration during angiogenesis [46] . Specifically, 
miRNA-29a-3p was found to be a selective marker identifying colorectal 
cancer patients, who are responding to anti-angiogenic treatments. Using 
mirDIP database portal we identified possible hsa-miR-29a-3p target genes 
in our tumor dataset. Interestingly, 81 targets overlap with upregulated 
genes and 87 targets with down-regulated genes (Supplementary Figure 7); 
including upregulated genes involved extracellular matrix modification and 
downregulated expression of Cyr61. Further studies are required to assess 
the role of the tumor hypoxia status and its effect on miRNA regulated 
angiogenesis. 
The balance between pro- and anti-angiogenic factors is usually disturbed 
during tumor development, resulting in tortuous and leaky vessels [47] . 
Analysis of tumor lysates showed reduced amounts of inflammatory and pro- 
angiogenic factors in HIF-1 α-KD tumors, such as Cyr61 or Dll4, which 
correlated with a normalized vasculature. Transcriptome analysis of sorted 
MC-38 tumor cells revealed upregulation of vessel-stabilizing factors such 
as endostatin, Pdgfa, Thbs2 in HIF-1 α-KD cells and reduced expression of 
pro-angiogenic factors such as Cyr61, Cox-2 and Angptl4 when compared to 
Mock tumors. Both findings on mRNA and protein levels are in agreement 
with histological evidence of more functional vessels detected in tumors with 
an impaired hypoxia response. Of note, HIF-1 α down-regulation resulted in 
lower transcript levels of genes such as Pellino1, Socs3 and Tnfrsf9 involved in 
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Figure 6. TRAF6-KD in MC-38 cells impairs tumor growth in the cecum and reduced subcutaneous tumor growth with changes in macrophages and 
angiogenesis. (A) Tumor mass in mice with MC-38 TRAF6-KD and Mock cell injection in the cecum 28 days postinjection. Mice without tumor have zero 
value. Mice from 2 independent experiments are presented (TRAF6-KD; n = 21). (B) The growth of subcutaneous tumors in mice injected either with TRAF6- 
KD or Mock MC-38 cells (n ≥ 10 per group). (C) Immunohistochemical analysis of cleaved-caspase-3 (cl-casp-3) and Ki67 staining in subcutaneous MC-38 
Mock and TRAF6-KD tumors. Random view fields were quantified for positive cells. pvf, per view field; scale bar = 200 μm. (D) Immunohistochemical 
analysis of subcutaneous tumors stained with the macrophage marker F4/80 Ab (top panels) were quantified (low panel). Three to 4 random view fields were 
analyzed per tumor; n = 4–5 per group. (E) Number of innate immune cells in orthotopic tumors represented as percentage of living CD45 + cells, determined 
by flow cytometr y; inflammator y monocytes, Ly6C hi ; dendritic cells, CD103 + /CD64 −; macrophages, (CD64 + /CD11c −/CD103 −; and tumor-associated 
macrophages – TAMs, CD64 + /CD11c + /CD103 −. Tumor analysis from two independent experiments ( n = 8). (F) Cell surface expression of polarization 
markers MHCII and CD206 was analyzed by flow cytometry, in parallel to the experiments shown under E. MFI from FMO control was subtracted from 
each sample; MFI, median fluorescence intensity. (G) Angiogenesis in TRAF6-KD and Mock tumors was analyzed using CD31 staining. The amount to 
vessel (CD31-positive staining) was quantified as percentage of total tumor area; vessel area and vessel density, respectively. Representative images of Mock 
and TRAF6-KD tumor are shown; scale bar = 100 μm. Statistical significance was assessed using the Mann-Whitney test; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 
0.001. 
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the inflammatory cascade. In human colorectal tumors, HIF-1 α expression 
positively correlated with genes shown to be regulated by HIF-1 α in MC-38 
tumors. Particularly, the observed Cyr61 mRNA level was previously reported 
to be a pro-angiogenic and tumor-promoting factor in renal, breast, pancreas 
and lung cancer cell lines [48-50] . We showed that intra-tumoral injection 
of Cyr61 resulted in enhanced angiogenesis associated with increased leaky 
vasculature and tumor hypoxia. Thus, the interference with the HIF-1 α
response in tumor cells leads to vessel normalization despite the intact hypoxia 
response in the tumor microenvironment. 
Tumor cell-derived NF- κB signaling is required for tumor initiation and 
progression in colorectal cancer [17 , 51] . Specific inactivation of the NF- 
κB pathway in epithelial cells attenuated the formation of colitis-associated 
colon cancer [52] . The modulation of NF- κB signaling in colon cancer has 
been linked to: increased chemokine expression associated with leukocyte 
infiltration and the microbiota-derived activation [53–55] . Bioinformatics 
analysis of the potential HIF-1 α interactome identified TRAF6, an upstream 
mediator of the NF- κB pathway, as a potential link between hypoxia signaling 
and the inflammatory cascade. MC-38 tumor cells with reduced TRAF6 
expression could not establish a tumor in the caecum, while tumors readily 
formed upon subcutaneous injection, albeit at a reduced size. Intestinal 
epithelial cells are in a constant contact with microbiota, which requires a 
tight control of inflammatory responses [54 , 56] , likely explaining why tumor 
cells with reduced TRAF6 activity and therefore reduced NF- κB signaling do 
not grow in the inflammatory environment of a colon. 
The histological analysis of TRAF6-KD tumors showed increased 
apoptosis (cleaved-caspase-3 + ), but also increased tumor cell proliferation 
as determined by Ki67 staining, when compared to Mock tumors. Ki67- 
staining is routinely being used for detection of proliferating tumors cells 
in animal models (e.g. [57] . However, recent study showed that Ki67 
expression is not always associated with cell proliferation, since the Ki67 
gene controls heterochromatin organization [58] . Targeted depletion of Ki67 
gene in the mouse gut epithelium did not result in any cell proliferation 
deficiency. Furthermore, cleaved-caspase 3 detection is a better prognostic 
marker than Ki67 staining in colorectal and endometrial cancers [59 , 60] . 
Recently, suppression of TRAF6 expression through overexpression of miR- 
146a resulted in deregulation of tumor cell proliferation in non-small 
cell lung cancer [61] . This finding is in agreement with our observation 
that TRAF6-KD tumors showed enhanced Ki67 staining, although we 
observed limited tumor growth due to enhanced apoptosis and reduced 
angiogenesis. 
TRAF6 is a unique member of the TRAF family of intracellular proteins, 
and is critically involved in the IL-1 receptor and Toll-like receptor family 
induced signal transduction leading to NF- κB activation [62] . Increased 
TRAF6 expression has been reported in various tumors, including colon, 
breast and melanoma cancers, as well as in lymphoid malignancies [38 , 39 , 63–
65] . Reportedly, TRAF6 is a K63-E3 ubiquitin ligase that ubiquitinates 
and stabilizes HIF-1 α in colon cancer cells independent of oxygen [38] . 
On contrary to previous findings, we observed enhanced endogenous 
levels of HIF-1 α interacting with TRAF6 under hypoxia. In breast cancer 
cells, TRAF6 overexpression correlated with increased HIF-1 α signaling 
and metastasis [39] . We identified TRAF6 as a potential binding partner 
of HIF-1 α in MC-38 tumor cells under hypoxia and confirmed that 
TRAF6 physically interacts with HIF-1 α as visualized by proximity ligation 
assay. Interestingly, we observed mostly cytoplasmic localization of TRAF6- 
HIF-1 α interactions. Our data indicate that TRAF6-HIF-1 α interaction 
contributes to tumor growth, primarily through modulation of angiogenesis, 
likely through stabilization of HIF-1 α proteins levels in tumor cells [38] . 
Both individual downregulations of either HIF-1 α or TRAF6 resulted in 
smaller tumors with reduced angiogenesis and normalized vasculature. Thus, 
targeting of hypoxia-inflammatory crosstalk represents an attractive approach 
for further development of improved delivery of standard or targeted cancer 
therapies. 
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Supplementary Figure 1. Characterization of HIF-1α-KD MC-38 cells. A) Transcript levels of 
HIF-1α were determined by qPCR after 8 hours incubation under normoxia (21% O2) or hypoxia 
(0.2% O2) stimulation. The expression levels of canonical HIF target genes VEGF-A (B) and CA-
IX (C) were quantified by RT-qPCR after 8 hours incubation under normoxia (21% O2) or hypoxia 
(0.2% O2) compared to mock controls. Expression levels were normalized to constitutively 
expressed ribosomal protein S12 mRNA levels. (D) Number of macrophages (CD64+/CD11c-) 
and tumor-associated macrophages - TAMs (CD64+/CD11c+) in orthotopic tumors represented 
as percentage of living CD45+ cells, determined by flow cytometry. (E) Cell surface expression of 
polarization markers MHCII and CD206 was analyzed by flow cytometry, in parallel to the 
experiments shown under D. MFI from FMO control was subtracted from each sample; MFI, 
median fluorescence intensity. Statistical significance was assessed using the Mann-Whitney 
test; ). *, p < 0.05; ***, p < 0.001. 
  
 
Supplementary Figure 2. Angiogenesis protein arrays of tumor lysates from HIF-1α KD and 
Mock cecal tumors. Total tumor lysates incubated on Angiogenesis Array. Dot blot pixel 
densities were quantified and normalized to internal manufacturer’s control and plotted as 
heatmap using web application from Functional Genomic Center Zurich.  
 
Supplementary Figure 3. Disease enrichment analysis of genes using human curated sets. 
A) List of genes from MC-38 HIF-1a KD cells versus Mock cells sorted from intracecal tumors 
were converted to human symbols and used for disease enrichment analysis using DOSE_3.14.0, 










Supplementary Figure 4. HIF-1α expression in clinical samples correlates with genes 
downregulated in HIF-KD sorted tumor cells. A) Correlation plots were drawn using the 
webtool In Silico Transcriptomics Ver. 2.1.3. (http://ist.medisapiens.com), focusing on 991 human 
colorectal cancer samples. All results were significant (p < 0.001) and positively correlated (r > 
0.2). B) Correlation plots using 594 colorectal cancer patient samples from Colorectal 
Adenocarcinoma dataset (TCGA, PanCancer Atlas; https://www.cbioportal.org/ ver. 3.4.3).  
 
Supplementary Figure 5. HIF-1α immunoprecipitation followed by TRAF-6 detection in 
murine colon carcinoma cell line MC-38 cells. Immunoprecipitation of HIF-1α in Mock and 
TRAF6-KD MC-38 cells, which were detected either with TRAF6 or HIF-1α Ab, respectively (n 
=3). Cells were incubated for 8 hours under normoxia (21% O2) or hypoxia (0.2% O2). 




Supplementary Figure 6. Characterization of TRAF6-KD MC-38 cells. A). Transcript levels of 
TRAF6 were determined by RT-qPCR.  mRNA expression levels of VEGF-A (B) and canonical 
TRAF6 target gene IL-6 (C) were quantified by RT-qPCR after LPS stimulation (1 µg/mL, 1 hour) 
compared to mock control and unstimulated cells. Expression levels were normalized to 
constitutively expressed ribosomal protein S12 mRNA levels. D) Experimental lung metastasis of 
Mock and TRAF6-KD MC-38 cells together with representative images of lung tumors after 28 
days of i.v. injection. Mice from two independent experiments are presented. Statistical 
significance was assessed using the Mann-Whitney test; *, p < 0.05; ***, p< 0.001. 
 
  
Supplemental experimental procedures 
 
Angiogenesis Array 
Perfused tumors were homogenized in 350 µl PBS containing protease inhibitors (complete 
EDTA-free, Roche) by using a Polytron (Brinkhan). Samples were spun down (15,000 x g for 15 
min at 4°C), supernatant was separated, and protein concentration was determined by BCA 
assay. Tumor lysate (400 μg) was incubated on a membrane spotted with the Mouse 
Angiogenesis Antibody Array (R&D Systems). Upon development, pixel density was analyzed 
with ImageQuant (GE Healthcare Life Sciences). Background signal density was subtracted and 
normalized to average density of reference spots. Up- and down-regulation of angiogenic factors 




Mice were intravenously (i.v.) injected with 300,000 MC-38GFP Mock or TRAF6-KD cells. Mice 
were sacrificed after 28 days and lungs were perfused with PBS. The number of metastatic foci 











Total cellular RNA was extracted using TRI Reagent (Sigma) or RNeasy Plus Mini Kit (Qiagen) 
following manufacturer’s recommendations. cDNA was synthesized from 1 µg of total RNA using 
Omniscript RT Kit (Qiagen). Quantitative qPCR was performed using KAPA SYBR Green Master 
Mix (Sigma) on a CFX96 Real-Time System (Biorad). Primers were purchased from Microsynth. 
 
Primer Sequence 
HIF-1a forward 5’-CATCCATGTGACCATGAGGA-3’ 
HIF-1a reverse 5’-CACGTTGCTGACTTGATGTT-3’ 
VEGF-A forward 5’-GTACCTCCACCATGCCAAGT-3’ 
VEGF-A reverse 5’-TCTCGTCGGGGTACTCCTGG-3’ 
CA-IX (Car9) forward 5’-GCCGCTACTACCGATATGAA-3’ 
CA-IX (Car9) reverse 5’-CACAAGGAAACGGAGAGAGT-3’ 
TRAF6 forward 5’-TCATCAGAGAACAGATGCCTAAT-3’ 
TRAF6 reverse 5’-TCATGTGCAACTGGGTATTCT-3’ 
IL-6 forward 5’-GTGGAAATGAGAAAAGAGTTGTGC-3’ 
IL-6 reverse 5’-ACCAGAGGAAATTTTCAATAGGC-3’ 
Cyr61 forward 5’-AGAGGCTTCCTGTCTTTGG-3’ 
Cyr61 reverse 5’-CACTCTGGGTTGTCATTGGT-3’ 
Pdgfa forward 5’-GATGAGGACCTGGGCTTGC-3’ 
Pdgfa reverse 5’-TCAGCCCCTACGGAGTCTATC-3’ 
Cox2 forward 5’-ACTGGGCCATGGAGTGGA-3’ 
Cox2 reverse 5’-GAGTGTCTTTGACTGTGGGGG-3’ 
Tnfrsf9 forward 5’-GCTGCCCTGAGATCGAAA-3’ 
Tnfrsf9 reverse 5’-GAAAGTACCAGGCTGACAGTTA-3’ 
S12 forward 5’-ACGTCAACACTGCTCTACAA-3’ 


















p Value Gene log2 
Ratio 
p Value Gene log2 
Ratio 
p Value 
Arsi 1.536 1.95E-08 Has2 0.7751 0.004355 Gm2048
9 
0.6574 0.006045 
Enpp2 1.515 3.13E-09 Etv1 0.7745 0.000191 Il1b 0.6566 0.01597 
Map1a 1.462 3.08E-08 Tnfrsf21 0.7729 0.000628 Cenpe 0.6563 0.01369 
Col18a1 1.343 2.56E-08 Stard10 0.7709 0.004949 Kirrel3 0.6562 0.0138 
Khdrbs3 1.239 3.55E-06 Ptpn3 0.7693 0.001993 Chd5 0.6556 0.01661 
Tmem54 1.234 1.54E-06 Ptpn6 0.7674 0.003255 Efnb1 0.6549 0.006815 
Nol3 1.168 1.57E-05 Sytl4 0.7672 0.004688 Srpx 0.6547 0.004553 
Lrrc15 1.151 2.45E-05 Cspg4 0.7628 0.003232 Mast2 0.6531 0.002916 
Pcsk9 1.11 3.54E-06 Plxnd1 0.7598 0.000469 Zbed4 0.6531 0.009298 
Fas 1.106 4.91E-06 Rbm19 0.7595 0.000418 Camsap
1 
0.6519 0.000963 
Stmn2 1.104 5.38E-05 Ednra 0.759 0.004118 Akap13 0.6518 0.003915 
Arap3 1.096 1.47E-05 Bcas1 0.7585 0.001786 Ptpn13 0.6504 0.01112 
Slc15a3 1.086 6.18E-06 Dkk2 0.7578 0.002947 Heg1 0.6492 0.001532 
Hs6st1 1.082 8.08E-07 Gm6880 0.7522 0.001189 Sertad4 0.648 0.002755 
Ston2 1.069 4.03E-05 Pogk 0.7514 1.39E-05 Gm684 0.647 0.01785 
Wfdc12 1.063 8.14E-05 Gdpd5 0.7507 0.002728 Spef1 0.6461 0.01251 
Tenm3 1.06 2.04E-05 Unc5b 0.7486 0.001513 S1pr1 0.6457 0.003973 
Card10 1.057 0.000102 Macf1 0.7476 0.001448 Ccr2 0.6437 0.01544 
Duox1 1.022 0.000161 Apol6 0.7464 0.006062 Kctd12 0.6436 0.01719 
Chst2 1.015 2.25E-05 Tep1 0.7463 0.004387 Gfra2 0.6431 0.005127 
Mdn1 1.001 2.02E-05 Cep290 0.7453 0.005887 Dock4 0.6424 0.003511 
Col2a1 0.9928 0.000176 Rgl1 0.7432 0.003597 Nav1 0.6419 0.002911 
Afap1l2 0.9886 5.15E-05 Kif26b 0.7411 0.000364 Abca1 0.6418 0.001482 
Fam198
b 
0.9873 0.000312 Dagla 0.7402 0.001675 Zfml 0.641 0.001805 
Extl1 0.985 1.16E-05 Akap9 0.74 0.004829 Ssh2 0.6406 0.002281 
Camk2a 0.9764 0.000325 Gbp5 0.7381 0.006021 Stat4 0.639 0.01567 
Arhgap2
6 
0.9761 1.47E-05 Ryr2 0.738 0.006528 Cd276 0.6384 0.000482 
Prodh 0.9698 9.07E-05 Ncam1 0.7365 0.004315 Abi3bp 0.6369 0.01008 
Serpinf1 0.9674 1.08E-07 Nin 0.7331 0.00072 Pcyox1l 0.6365 0.01231 
Slc22a2
3 
0.9619 0.000451 Lama4 0.7304 0.006208 Myh3 0.6361 0.01906 
Nid2 0.9604 0.000284 Arid5a 0.73 0.002825 Fbln5 0.6351 0.01692 
Aldh1a3 0.9577 0.000477 Adgra3 0.7294 0.000428 C1qtnf1 0.6347 0.01604 
Ttn 0.9508 0.000385 Car14 0.7294 0.007353 Slc26a9 0.6333 0.01604 
2900026
A02Rik 
0.9474 0.000179 Neto2 0.7267 0.001744 Slitrk5 0.6314 0.02081 
Ptn 0.9462 0.000295 Zfp600 0.7254 0.003771 Fgfr3 0.63 0.02071 
Icam1 0.9447 0.000345 Tex13 0.7242 0.00038 Rgs5 0.6283 0.02132 
Dppa2 0.9439 4.25E-05 Myo18a 0.723 0.001961 Hip1 0.624 0.003119 
Gxylt2 0.9403 0.000157 Ciita 0.7177 0.003535 Zfc3h1 0.6232 0.004891 
Cyp7b1 0.9345 0.000267 Nckap5 0.7155 0.009098 Eml5 0.6227 0.02289 
Cd200 0.9345 0.000439 Pstpip2 0.7143 0.008768 Uhrf1bp1 0.6222 0.00068 
Apcdd1 0.9304 0.000658 Tcn2 0.714 0.002885 Dennd3 0.6222 0.01726 
Scml4 0.9222 0.000547 Plxnb1 0.7139 0.002781 Wisp1 0.6217 0.001894 
Mdfi 0.9219 0.000647 Cep162 0.7117 0.00327 Apobr 0.6217 0.007581 
Ctxn1 0.9142 0.000354 Nhs 0.7106 0.009585 Lpar1 0.6199 0.01469 
Gli1 0.9086 0.000273 Atp2b4 0.7098 0.005786 Golga3 0.6197 0.001715 
Xylt1 0.9067 0.000615 Nlrc5 0.7096 0.00061 Creb3l1 0.6192 0.01968 
Mid1 0.8983 4.39E-05 Chrnd 0.7068 0.005292 Urb1 0.6184 0.001338 
Sorcs2 0.8877 0.000265 Crip1 0.7064 0.00975 Sh3pxd2
a 
0.6182 0.004064 
Ank1 0.8854 0.000269 Xlr4b 0.7056 0.007636 Dab2 0.6179 0.007381 
Ceacam
20 
0.8782 0.00047 Prokr1 0.7042 0.009533 Col27a1 0.6173 0.01624 
Spib 0.8771 0.001236 Slfn9 0.7029 0.001994 Nfkbie 0.6165 0.003431 
Mov10l1 0.8757 0.001091 Apc 0.702 0.000794 Gfpt2 0.6162 0.02175 
Bace2 0.8751 0.000619 Slc16a9 0.7007 0.0106 Ankrd26 0.6154 0.005389 
Pgbd5 0.8729 0.001324 Ankrd11 0.6984 0.006901 Tmem17
3 
0.615 0.001167 
Lama5 0.8723 7.65E-05 Arap2 0.6976 0.01055 Penk 0.6145 0.0161 
Slc4a5 0.872 0.00141 Tvp23a 0.6949 0.005427 Ccdc24 0.6142 0.00579 
Tspan2 0.8641 0.001211 Fyco1 0.6929 0.001719 Gm1315
1 
0.6134 0.02535 
Amigo2 0.8617 0.000136 Lbx1 0.689 0.00907 Serpina3
f 
0.6131 0.0152 
Crb2 0.8587 0.00113 2010005
H15Rik 
0.689 0.012 Myo1e 0.6129 0.005001 
Golgb1 0.8541 0.001176 Bcl2 0.6878 0.004286 Abca13 0.6127 0.01598 
Prune2 0.8463 5.17E-06 Cd9 0.6875 0.00227 Rgma 0.6122 0.01227 
Slamf8 0.843 0.000239 Rabl6 0.687 0.00023 Wnt6 0.6121 0.02132 
Col3a1 0.841 5.03E-05 Adamtsl3 0.6864 0.00092 Tlr12 0.6115 0.02116 
Cd248 0.8396 0.000449 Dppa4 0.6861 0.01066 Baz1b 0.6106 0.000965 
Zbtb40 0.839 0.000141 Lynx1 0.6855 0.005872 Synj2 0.6095 0.003389 
Map3k5 0.8384 0.000552 Tmem2 0.6848 0.00245 Slit2 0.6092 0.001397 
Mlph 0.8372 0.000556 Il2rg 0.684 0.004172 Sema4a 0.6087 0.01751 
Bptf 0.8289 0.000474 Gm1314
5 
0.6822 0.002066 Zfp251 0.608 0.00658 
Plxna1 0.8279 0.000332 Scara5 0.6821 0.005129 Dennd2a 0.6078 0.00335 
Vegfc 0.826 0.001686 Gdf11 0.6818 0.000524 Thbs2 0.6078 0.01377 
Notch1 0.8257 0.000457 Flrt2 0.6817 0.003201 P2rx7 0.6076 0.01264 





0.8171 0.000276 Mtcl1 0.6797 0.01184 Spata13 0.6048 0.01287 
Slx4 0.8147 0.000411 Itga1 0.679 0.01299 Akna 0.6026 0.01763 
Plxna2 0.8112 0.000271 Pid1 0.6777 0.006235 Flrt3 0.6013 0.02414 
Gm1538
6 
0.8108 0.002021 Tph2 0.6777 0.01221 Cntrl 0.6009 0.02364 
Sema6a 0.8078 0.00179 Gareml 0.6763 0.01362 Sema3c 0.5988 0.02472 
Hsph1 0.8065 4.91E-05 Golga4 0.6755 0.007958 Wdfy3 0.5976 0.004101 
Ccdc36 0.8054 0.002731 Fat4 0.6754 0.006058 Grip1 0.5972 0.0281 
Rorb 0.8051 0.002187 Trak2 0.6751 0.000293 Col11a2 0.5947 0.02764 
Abca3 0.805 0.003169 Col1a1 0.6743 0.01253 Slc2a13 0.5941 0.01877 
Pde2a 0.8045 0.002227 Syne2 0.674 0.008263 Uchl1 0.5938 0.0213 
Trpa1 0.7991 0.002311 Rps6kc1 0.6714 0.005068 Trim56 0.5928 0.007752 
Zfp936 0.7985 0.003183 Chd7 0.6703 0.0145 Lck 0.5928 0.02781 
Trip11 0.7963 0.000364 A4galt 0.6693 0.01468 Bdp1 0.5927 0.007637 
Col5a2 0.7926 0.000193 Nov 0.6667 0.005249 Lgi4 0.5925 0.02681 
Cd38 0.7915 0.000715 Magi1 0.6663 0.01477 St3gal1 0.5923 0.007066 
Tmem11
9 
0.7903 0.00275 Gli2 0.6633 0.01559 Tnrc6c 0.592 0.01445 
Spry1 0.79 0.003254 Nipbl 0.6615 0.001738 Serpinh1 0.5919 0.01216 
Amot 0.7884 0.000381 Tcf20 0.6602 0.002459 Ccne1 0.5915 0.007431 
Fjx1 0.7831 0.003726 Pprc1 0.6595 0.001264 C2cd2 0.5905 0.006618 
Lbp 0.7794 0.003456 Nol4l 0.6586 0.01597 Lamc1 0.5902 0.003146 
Pdgfa 0.7786 0.0003 Ccr7 0.6578 0.01648 Fam212b 0.5901 0.0109 
Cntnap4 0.776 0.004216 








p Value Gene log2 
Ratio 




















































































































































































































































0.02147 Rpl22l1 -0.731 0.00171
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Supplementary Figure 7. Predicted target genes for hsa-miR-29a-3p, overlapping with 
up- and down-regulated genes identified in sorted MC-38 cells in sorted HIF-KD tumor 
cells vs. sorted Mock cells. hsa-miR-29a-3p [1] target genes were identified using MicroRNA 
Data Integration Portal, mirDIP version 4.1.11.1 (Database version 4.1.0.3) 
(http://ophid.utoronto.ca/mirDIP) [2], using all 30 datasets, high confidence level, and bi-
directional search option. While the table lists all known sources for individual genes, there 
are 81 unique up-regulated targets and 87 unique down-regulated targets. 
 
Upregulated Gene targeted by mir29 
 Gene 
Symbol     
Uniprot       Source   Confidence 
 
    class     
          
UP ABCA13 Q86UQ4 microrna.org High 
UP ADGRA3 Q8IWK6 microrna.org Very High 
UP AKAP13 Q12802 CoMeTa High 
UP AKAP13 Q12802 ElMMo3 Very High 
UP AKAP13 Q12802 MultiMiTar High 
UP AKAP13 Q12802 PACCMIT High 
UP AKAP13 Q12802 TargetRank Very High 
UP AKAP13 Q12802 TargetScan Very High 
UP AKAP13 Q12802 miRTar2GO High 
UP AKAP13 Q12802 MirAncesTar High 
UP AKAP13 Q12802 microrna.org High 
UP AMOT Q4VCS5 CoMeTa High 
UP AMOT Q4VCS5 Cupid High 
UP AMOT Q4VCS5 ElMMo3 Very High 
UP AMOT Q4VCS5 MAMI High 
UP AMOT Q4VCS5 MultiMiTar High 
UP AMOT Q4VCS5 PACCMIT High 
UP AMOT Q4VCS5 TargetRank Very High 
UP AMOT Q4VCS5 TargetScan Very High 
UP AMOT Q4VCS5 miRTar2GO High 
UP AMOT Q4VCS5 microrna.org High 
UP ANK1 P16157 CoMeTa High 
UP ANK1 P16157 Cupid Very High 
UP ANK1 P16157 ElMMo3 Very High 
UP ANK1 P16157 PACCMIT High 
UP ANK1 P16157 TargetScan Very High 
UP APC P25054 TargetScan Very High 
UP APC P25054 microrna.org Very High 
UP APOL6 Q9BWW8 miRTar2GO High 
UP ARAP2 Q8WZ64 microrna.org High 
UP ARAP3 Q8WWN8 CoMeTa High 
UP ARAP3 Q8WWN8 ElMMo3 High 
UP ARAP3 Q8WWN8 MAMI High 
UP ARAP3 Q8WWN8 microrna.org High 
UP ATP2B4 P23634 CoMeTa Very High 
UP ATP2B4 P23634 Cupid Very High 
UP ATP2B4 P23634 ElMMo3 Very High 
UP ATP2B4 P23634 MultiMiTar High 
UP ATP2B4 P23634 PACCMIT High 
UP ATP2B4 P23634 TargetRank High 
UP ATP2B4 P23634 TargetScan Very High 
UP ATP2B4 P23634 miRTar2GO High 
UP ATP2B4 P23634 microrna.org High 
UP BCL2 P10415 CoMeTa High 
UP BDP1 A6H8Y1 miRTar2GO High 
UP BPTF Q12830 Cupid Very High 
UP BPTF Q12830 ElMMo3 High 
UP CAMK2A Q9UQM7 MultiMiTar High 
UP CAMSAP1 Q5T5Y3 miRTar2GO High 
UP CCDC36 Q8IYA8 MAMI High 
UP CCDC36 Q8IYA8 microrna.org Very High 
UP CCNE1 P24864 Cupid Very High 
UP CCNE1 P24864 ElMMo3 High 
UP CCNE1 P24864 miRTar2GO High 
UP CD276 Q5ZPR3 ElMMo3 Very High 
UP CD276 Q5ZPR3 MAMI High 
UP CD276 Q5ZPR3 PACCMIT High 
UP CD276 Q5ZPR3 TargetRank Very High 
UP CD276 Q5ZPR3 TargetScan Very High 
UP CD276 Q5ZPR3 miRTar2GO High 
UP CD276 Q5ZPR3 microrna.org High 
UP COL1A1 P02452 CoMeTa High 
UP COL1A1 P02452 Cupid Very High 
UP COL1A1 P02452 DIANA High 
UP COL1A1 P02452 ElMMo3 Very High 
UP COL1A1 P02452 GenMir++ Very High 
UP COL1A1 P02452 MAMI Very High 
UP COL1A1 P02452 Mirza-G High 
UP COL1A1 P02452 MultiMiTar High 
UP COL1A1 P02452 PACCMIT High 
UP COL1A1 P02452 TargetRank High 
UP COL1A1 P02452 TargetScan Very High 
UP COL1A1 P02452 miRTar2GO High 
UP COL1A1 P02452 microrna.org High 
UP COL27A1 Q8IZC6 DIANA High 
UP COL27A1 Q8IZC6 PACCMIT High 
UP COL27A1 Q8IZC6 TargetScan Very High 
UP COL2A1 P02458 CoMeTa High 
UP COL2A1 P02458 DIANA Very High 
UP COL2A1 P02458 ElMMo3 Very High 
UP COL2A1 P02458 MirTar High 
UP COL2A1 P02458 PicTar Very High 
UP COL2A1 P02458 TargetRank Very High 
UP COL2A1 P02458 TargetScan Very High 
UP COL2A1 P02458 miRDB High 
UP COL2A1 P02458 microrna.org Very High 
UP COL3A1 P02461 CoMeTa Very High 
UP COL3A1 P02461 Cupid Very High 
UP COL3A1 P02461 DIANA Very High 
UP COL3A1 P02461 ElMMo3 Very High 
UP COL3A1 P02461 MAMI Very High 
UP COL3A1 P02461 MirTar Very High 
UP COL3A1 P02461 Mirza-G High 
UP COL3A1 P02461 MultiMiTar High 
UP COL3A1 P02461 PACCMIT High 
UP COL3A1 P02461 PicTar Very High 
UP COL3A1 P02461 TargetRank Very High 
UP COL3A1 P02461 TargetScan Very High 
UP COL3A1 P02461 miRDB High 
UP COL3A1 P02461 microrna.org Very High 
UP COL5A2 P05997 CoMeTa Very High 
UP COL5A2 P05997 Cupid Very High 
UP COL5A2 P05997 DIANA High 
UP COL5A2 P05997 ElMMo3 Very High 
UP COL5A2 P05997 MirTar High 
UP COL5A2 P05997 Mirza-G High 
UP COL5A2 P05997 PACCMIT High 
UP COL5A2 P05997 PicTar Very High 
UP COL5A2 P05997 TargetScan Very High 
UP COL5A2 P05997 miRDB High 
UP COL5A2 P05997 miRTar2GO High 
UP COL5A2 P05997 microrna.org Very High 
UP CSPG4 Q6UVK1 ElMMo3 High 
UP CSPG4 Q6UVK1 MAMI High 
UP CSPG4 Q6UVK1 PACCMIT High 
UP CSPG4 Q6UVK1 TargetScan Very High 
UP CSPG4 Q6UVK1 microrna.org High 
UP DENND3 A2RUS2 microrna.org High 
UP EML5 Q05BV3 Cupid Very High 
UP EML5 Q05BV3 DIANA High 
UP EML5 Q05BV3 ElMMo3 Very High 
UP EML5 Q05BV3 MAMI High 
UP EML5 Q05BV3 PACCMIT High 
UP EML5 Q05BV3 TargetScan Very High 
UP EML5 Q05BV3 miRDB High 
UP EML5 Q05BV3 miRTar2GO High 
UP EML5 Q05BV3 microrna.org High 
UP ENPP2 Q13822 CoMeTa High 
UP ENPP2 Q13822 Cupid Very High 
UP ENPP2 Q13822 TargetRank Very High 
UP ENPP2 Q13822 TargetScan Very High 
UP ENPP2 Q13822 microrna.org Very High 
UP FAS P25445 CoMeTa High 
UP FAS P25445 microrna.org High 
UP GLI2 P10070 miRTar2GO High 
UP GLI2 P10070 microrna.org High 
UP GOLGA3 Q08378 miRTar2GO High 
UP GRIP1 Q9Y3R0 DIANA Very High 
UP GRIP1 Q9Y3R0 ElMMo3 Very High 
UP GRIP1 Q9Y3R0 MAMI High 
UP GRIP1 Q9Y3R0 TargetScan Very High 
UP GRIP1 Q9Y3R0 miRTar2GO High 
UP GRIP1 Q9Y3R0 microrna.org Very High 
UP GXYLT2 A0PJZ3 Cupid Very High 
UP GXYLT2 A0PJZ3 DIANA High 
UP GXYLT2 A0PJZ3 ElMMo3 Very High 
UP GXYLT2 A0PJZ3 TargetScan Very High 
UP GXYLT2 A0PJZ3 miRTar2GO High 
UP GXYLT2 A0PJZ3 microrna.org Very High 
UP HAS2 Q92819 TargetScan Very High 
UP HIP1 O00291 CoMeTa High 
UP HIP1 O00291 ElMMo3 High 
UP HIP1 O00291 TargetScan Very High 
UP HIP1 O00291 MirAncesTar High 
UP KIF26B Q2KJY2 CoMeTa High 
UP KIF26B Q2KJY2 Cupid Very High 
UP KIF26B Q2KJY2 DIANA Very High 
UP KIF26B Q2KJY2 ElMMo3 Very High 
UP KIF26B Q2KJY2 MAMI High 
UP KIF26B Q2KJY2 PACCMIT High 
UP KIF26B Q2KJY2 TargetRank Very High 
UP KIF26B Q2KJY2 TargetScan Very High 
UP KIF26B Q2KJY2 miRDB High 
UP KIF26B Q2KJY2 microrna.org Very High 
UP LAMC1 P11047 CoMeTa Very High 
UP LAMC1 P11047 DIANA High 
UP LAMC1 P11047 ElMMo3 Very High 
UP LAMC1 P11047 MAMI Very High 
UP LAMC1 P11047 Mirza-G High 
UP LAMC1 P11047 PACCMIT High 
UP LAMC1 P11047 TargetRank Very High 
UP LAMC1 P11047 TargetScan Very High 
UP LAMC1 P11047 miRDB High 
UP LAMC1 P11047 MirAncesTar High 
UP LAMC1 P11047 microrna.org Very High 
UP LBP P18428 CoMeTa High 
UP MAGI1 Q96QZ7 CoMeTa High 
UP MDN1 Q9NU22 miRTar2GO High 
UP MMP28 Q9H239 microrna.org High 
UP MYO18A Q92614 ElMMo3 High 
UP MYO18A Q92614 MultiMiTar High 
UP MYO18A Q92614 PACCMIT High 
UP MYO18A Q92614 TargetScan Very High 
UP NAV1 Q8NEY1 CoMeTa High 
UP NAV1 Q8NEY1 Cupid Very High 
UP NAV1 Q8NEY1 DIANA High 
UP NAV1 Q8NEY1 ElMMo3 Very High 
UP NAV1 Q8NEY1 MirTar High 
UP NAV1 Q8NEY1 Mirza-G High 
UP NAV1 Q8NEY1 MultiMiTar High 
UP NAV1 Q8NEY1 PACCMIT High 
UP NAV1 Q8NEY1 TargetRank High 
UP NAV1 Q8NEY1 TargetScan Very High 
UP NAV1 Q8NEY1 miRTar2GO High 
UP NAV1 Q8NEY1 microrna.org High 
UP NCAM1 P13591 CoMeTa High 
UP NCAM1 P13591 microrna.org High 
UP NCKAP5 O14513 Cupid Very High 
UP NCKAP5 O14513 ElMMo3 Very High 
UP NCKAP5 O14513 MAMI High 
UP NCKAP5 O14513 Mirza-G High 
UP NCKAP5 O14513 PACCMIT High 
UP NCKAP5 O14513 TargetRank Very High 
UP NCKAP5 O14513 TargetScan Very High 
UP NCKAP5 O14513 miRDB High 
UP NCKAP5 O14513 microrna.org Very High 
UP NID2 Q14112 CoMeTa High 
UP NID2 Q14112 Cupid Very High 
UP NID2 Q14112 ElMMo3 Very High 
UP NID2 Q14112 MAMI High 
UP NID2 Q14112 microrna.org High 
UP NIN Q8N4C6 miRTar2GO High 
UP NIPBL Q6KC79 microrna.org High 
UP NOL4L Q96MY1 Cupid Very High 
UP NOL4L Q96MY1 ElMMo3 Very High 
UP NOL4L Q96MY1 Mirza-G High 
UP NOL4L Q96MY1 TargetScan Very High 
UP NOL4L Q96MY1 miRTar2GO High 
UP NOL4L Q96MY1 MirAncesTar High 
UP NOL4L Q96MY1 microrna.org High 
UP PCSK9 Q8NBP7 miRTar2GO High 
UP PDGFA P04085 MultiMiTar High 
UP PENK P01210 MAMI High 
UP PLXNA1 Q9UIW2 CoMeTa High 
UP PLXNA1 Q9UIW2 ElMMo3 High 
UP PLXNA1 Q9UIW2 MultiMiTar High 
UP PLXNA1 Q9UIW2 PicTar Very High 
UP PLXNA1 Q9UIW2 TargetRank Very High 
UP PLXNA1 Q9UIW2 TargetScan Very High 
UP PLXNA1 Q9UIW2 miRDB High 
UP PLXNA1 Q9UIW2 miRTar2GO High 
UP PLXNA1 Q9UIW2 microrna.org High 
UP RABL6 Q3YEC7 miRTar2GO High 
UP RABL6 Q3YEC7 microrna.org High 
UP SCML4 Q8N228 microrna.org High 
UP SEMA3C Q99985 miRTar2GO High 
UP SEMA6A Q9H2E6 microrna.org High 
UP SERPINH1 P50454 CoMeTa Very High 
UP SERPINH1 P50454 Cupid Very High 
UP SERPINH1 P50454 DIANA High 
UP SERPINH1 P50454 ElMMo3 Very High 
UP SERPINH1 P50454 MultiMiTar High 
UP SERPINH1 P50454 TargetScan Very High 
UP SERTAD4 Q9NUC0 MirTar High 
UP SERTAD4 Q9NUC0 TargetRank High 
UP SERTAD4 Q9NUC0 microrna.org High 
UP SH3PXD2A Q5TCZ1 CoMeTa High 
UP SH3PXD2A Q5TCZ1 Cupid Very High 
UP SH3PXD2A Q5TCZ1 DIANA Very High 
UP SH3PXD2A Q5TCZ1 ElMMo3 Very High 
UP SH3PXD2A Q5TCZ1 Mirza-G High 
UP SH3PXD2A Q5TCZ1 PACCMIT Very High 
UP SH3PXD2A Q5TCZ1 TargetRank High 
UP SH3PXD2A Q5TCZ1 TargetScan Very High 
UP SH3PXD2A Q5TCZ1 miRTar2GO High 
UP SLC2A13 Q96QE2 MultiMiTar High 
UP SLITRK5 O94991 Cupid Very High 
UP SPRY1 O43609 CoMeTa High 
UP SPRY1 O43609 Cupid Very High 
UP SPRY1 O43609 ElMMo3 Very High 
UP SPRY1 O43609 Mirza-G High 
UP SPRY1 O43609 PACCMIT High 
UP SPRY1 O43609 TargetScan Very High 
UP SPRY1 O43609 microrna.org Very High 
UP SSH2 Q76I76 ElMMo3 High 
UP SSH2 Q76I76 MultiMiTar High 
UP SSH2 Q76I76 PACCMIT High 
UP SSH2 Q76I76 miRTar2GO High 
UP STMN2 Q93045 DIANA Very High 
UP STMN2 Q93045 ElMMo3 Very High 
UP STMN2 Q93045 PACCMIT High 
UP STMN2 Q93045 TargetScan Very High 
UP SYNE2 Q8WXH0 CoMeTa High 
UP SYNE2 Q8WXH0 microrna.org High 
UP SYNJ2 O15056 microrna.org High 
UP TENM3 Q9P273 CoMeTa High 
UP TENM3 Q9P273 Cupid High 
UP TENM3 Q9P273 ElMMo3 Very High 
UP TENM3 Q9P273 TargetScan Very High 
UP TENM3 Q9P273 microrna.org High 
UP THBS2 P35442 TargetRank Very High 
UP THBS2 P35442 microrna.org Very High 
UP TMEM159 Q96B96 microrna.org High 
UP TNRC6C Q9HCJ0 microrna.org High 
UP TRAK2 O60296 ElMMo3 High 
UP TRAK2 O60296 MultiMiTar High 
UP TRAK2 O60296 PACCMIT High 
UP TRAK2 O60296 TargetScan Very High 
UP TRAK2 O60296 miRTar2GO High 
UP TRAK2 O60296 microrna.org High 
UP TRIM56 Q9BRZ2 microrna.org High 
UP UHRF1BP1 Q6BDS2 ElMMo3 High 
UP UHRF1BP1 Q6BDS2 MultiMiTar High 
UP UHRF1BP1 Q6BDS2 miRTar2GO High 
UP UHRF1BP1 Q6BDS2 microrna.org High 
UP UNC5B Q8IZJ1 microrna.org High 
UP URB1 O60287 TargetScan Very High 
UP WDFY3 Q8IZQ1 CoMeTa Very High 
UP WDFY3 Q8IZQ1 Cupid Very High 
UP WDFY3 Q8IZQ1 ElMMo3 Very High 
UP WDFY3 Q8IZQ1 MultiMiTar High 
UP WDFY3 Q8IZQ1 PACCMIT High 
UP WDFY3 Q8IZQ1 TargetScan Very High 
UP WDFY3 Q8IZQ1 miRTar2GO High 
UP WISP1 O95388 TargetScan Very High 
UP WISP1 O95388 MirAncesTar High 
UP WISP1 O95388 microrna.org High 
UP XYLT1 Q86Y38 MultiMiTar High 
UP ZBTB40 Q9NUA8 CoMeTa High 
UP ZBTB40 Q9NUA8 Cupid Very High 
UP ZBTB40 Q9NUA8 ElMMo3 Very High 
UP ZBTB40 Q9NUA8 MAMI High 
UP ZBTB40 Q9NUA8 MultiMiTar High 
UP ZBTB40 Q9NUA8 PACCMIT High 
UP ZBTB40 Q9NUA8 TargetScan Very High 
UP ZBTB40 Q9NUA8 MirAncesTar High 
UP ZBTB40 Q9NUA8 microrna.org High 
UP ZNF251 Q9BRH9 microrna.org High 
UP ZNF616 Q08AN1 microrna.org High 
 
Downregulated Gene targeted by mir29 
 Gene 
Symbol     
Uniprot       Source   Confidence 
 
    class     
          
DOWN ABHD18 Q0P651 TargetScan Very High 
DOWN ADAM22 Q9P0K1 ElMMo3 Very High 
DOWN ADAM8 P78325 microrna.org High 
DOWN AK4 P27144 CoMeTa High 
DOWN AK4 P27144 ElMMo3 High 
DOWN AK4 P27144 microrna.org High 
DOWN AMPD3 Q01432 MultiMiTar High 
DOWN AMPD3 Q01432 microrna.org High 
DOWN ANGPTL4 Q9BY76 CoMeTa High 
DOWN ANGPTL4 Q9BY76 ElMMo3 High 
DOWN ANGPTL4 Q9BY76 MAMI Very High 
DOWN ANGPTL4 Q9BY76 microrna.org High 
DOWN ARRDC3 Q96B67 Cupid Very High 
DOWN ARRDC3 Q96B67 DIANA High 
DOWN ARRDC3 Q96B67 ElMMo3 Very High 
DOWN ARRDC3 Q96B67 MirTar High 
DOWN ARRDC3 Q96B67 Mirza-G High 
DOWN ARRDC3 Q96B67 MultiMiTar High 
DOWN ARRDC3 Q96B67 PACCMIT High 
DOWN ARRDC3 Q96B67 TargetRank High 
DOWN ARRDC3 Q96B67 TargetScan Very High 
DOWN ARRDC3 Q96B67 miRDB High 
DOWN ARRDC3 Q96B67 miRTar2GO High 
DOWN ARRDC3 Q96B67 MirAncesTar High 
DOWN ARRDC3 Q96B67 microrna.org Very High 
DOWN BMT2 Q1RMZ1 Cupid Very High 
DOWN BMT2 Q1RMZ1 DIANA High 
DOWN BMT2 Q1RMZ1 ElMMo3 Very High 
DOWN BMT2 Q1RMZ1 Mirza-G High 
DOWN BMT2 Q1RMZ1 PACCMIT High 
DOWN BMT2 Q1RMZ1 TargetRank High 
DOWN BMT2 Q1RMZ1 TargetScan Very High 
DOWN BMT2 Q1RMZ1 miRDB High 
DOWN BMT2 Q1RMZ1 miRTar2GO High 
DOWN BMT2 Q1RMZ1 microrna.org Very High 
DOWN BSG P35613 microrna.org High 
DOWN BTG1 P62324 microrna.org Very High 
DOWN BTG2 P78543 CoMeTa High 
DOWN BTG2 P78543 Cupid Very High 
DOWN BTG2 P78543 DIANA High 
DOWN BTG2 P78543 ElMMo3 Very High 
DOWN BTG2 P78543 MultiMiTar High 
DOWN BTG2 P78543 PACCMIT High 
DOWN BTG2 P78543 TargetScan Very High 
DOWN BTG2 P78543 miRTar2GO High 
DOWN CAV2 P51636 CoMeTa Very High 
DOWN CAV2 P51636 Cupid Very High 
DOWN CAV2 P51636 DIANA High 
DOWN CAV2 P51636 ElMMo3 Very High 
DOWN CAV2 P51636 MAMI Very High 
DOWN CAV2 P51636 Mirza-G High 
DOWN CAV2 P51636 PACCMIT High 
DOWN CAV2 P51636 TargetScan Very High 
DOWN CAV2 P51636 miRDB High 
DOWN CAV2 P51636 miRTar2GO High 
DOWN CAV2 P51636 microrna.org Very High 
DOWN CD109 Q6YHK3 miRTar2GO High 
DOWN CDKN1A P38936 miRTar2GO High 
DOWN CDKN2D P55273 miRTar2GO High 
DOWN CELF2 O95319 CoMeTa Very High 
DOWN CELF2 O95319 Cupid Very High 
DOWN CELF2 O95319 ElMMo3 Very High 
DOWN CELF2 O95319 Mirza-G High 
DOWN CELF2 O95319 MultiMiTar High 
DOWN CELF2 O95319 PACCMIT High 
DOWN CELF2 O95319 TargetRank Very High 
DOWN CELF2 O95319 TargetScan Very High 
DOWN CELF2 O95319 miRTar2GO High 
DOWN CELF2 O95319 microrna.org Very High 
DOWN CIRBP Q14011 microrna.org High 
DOWN CNR1 P21554 CoMeTa High 
DOWN CNR1 P21554 Cupid Very High 
DOWN CNR1 P21554 ElMMo3 Very High 
DOWN CNR1 P21554 MultiMiTar High 
DOWN CNR1 P21554 PACCMIT High 
DOWN CNR1 P21554 TargetRank Very High 
DOWN CNR1 P21554 TargetScan Very High 
DOWN CNR1 P21554 MirAncesTar High 
DOWN CNR1 P21554 microrna.org High 
DOWN CYR61 O00622 miRTar2GO High 
DOWN DMXL1 Q9Y485 MultiMiTar High 
DOWN DMXL1 Q9Y485 microrna.org High 
DOWN DNAJC5 Q9H3Z4 miRTar2GO High 
DOWN DUSP4 Q13115 miRTar2GO High 
DOWN EPHA7 Q15375 microrna.org High 
DOWN EPS8L2 Q9H6S3 MAMI High 
DOWN FAM117B Q6P1L5 miRTar2GO High 
DOWN FAM117B Q6P1L5 microrna.org High 
DOWN FAM46B Q96A09 MAMI High 
DOWN FGF7 P21781 microrna.org Very High 
DOWN FRAT2 O75474 CoMeTa High 
DOWN FRAT2 O75474 Cupid Very High 
DOWN FRAT2 O75474 ElMMo3 Very High 
DOWN FRAT2 O75474 PACCMIT High 
DOWN FRAT2 O75474 TargetRank Very High 
DOWN FRAT2 O75474 TargetScan Very High 
DOWN FRAT2 O75474 miRTar2GO High 
DOWN FRAT2 O75474 MirAncesTar High 
DOWN FRAT2 O75474 microrna.org Very High 
DOWN GNG2 P59768 Cupid Very High 
DOWN GNG2 P59768 ElMMo3 High 
DOWN GNG2 P59768 PACCMIT High 
DOWN GNG2 P59768 TargetScan Very High 
DOWN GNG2 P59768 microrna.org High 
DOWN GPI P06744 MirTar High 
DOWN GPI P06744 miRTar2GO High 
DOWN GPI P06744 microrna.org High 
DOWN GRIA4 P48058 MultiMiTar High 
DOWN GRIA4 P48058 microrna.org High 
DOWN GYS1 P13807 microrna.org High 
DOWN HBEGF Q99075 CoMeTa High 
DOWN HBEGF Q99075 Cupid Very High 
DOWN HBEGF Q99075 DIANA High 
DOWN HBEGF Q99075 ElMMo3 Very High 
DOWN HBEGF Q99075 MultiMiTar High 
DOWN HBEGF Q99075 TargetScan Very High 
DOWN HBEGF Q99075 miRTar2GO High 
DOWN HBEGF Q99075 microrna.org High 
DOWN HBP1 O60381 CoMeTa Very High 
DOWN HBP1 O60381 Cupid Very High 
DOWN HBP1 O60381 DIANA Very High 
DOWN HBP1 O60381 ElMMo3 Very High 
DOWN HBP1 O60381 MAMI Very High 
DOWN HBP1 O60381 MirTar High 
DOWN HBP1 O60381 Mirza-G High 
DOWN HBP1 O60381 MultiMiTar High 
DOWN HBP1 O60381 PACCMIT High 
DOWN HBP1 O60381 TargetRank Very High 
DOWN HBP1 O60381 TargetScan Very High 
DOWN HBP1 O60381 miRDB High 
DOWN HBP1 O60381 microrna.org Very High 
DOWN HERC3 Q15034 microrna.org High 
DOWN HIGD1A Q9Y241 miRTar2GO High 
DOWN HLF Q16534 CoMeTa High 
DOWN HLF Q16534 ElMMo3 Very High 
DOWN HLF Q16534 TargetRank Very High 
DOWN HLF Q16534 TargetScan Very High 
DOWN HLF Q16534 microrna.org High 
DOWN HOGA1 Q86XE5 microrna.org High 
DOWN HOMER1 Q86YM7 TargetScan Very High 
DOWN ID3 Q02535 MultiMiTar High 
DOWN ID3 Q02535 miRTar2GO High 
DOWN ID3 Q02535 microrna.org High 
DOWN IER2 Q9BTL4 miRTar2GO High 
DOWN ISLR2 Q6UXK2 Cupid Very High 
DOWN ISLR2 Q6UXK2 DIANA High 
DOWN ISLR2 Q6UXK2 ElMMo3 Very High 
DOWN ISLR2 Q6UXK2 PACCMIT High 
DOWN ISLR2 Q6UXK2 TargetScan Very High 
DOWN ISLR2 Q6UXK2 MirAncesTar High 
DOWN ISLR2 Q6UXK2 microrna.org High 
DOWN JUN P05412 microrna.org High 
DOWN KDM4B O94953 CoMeTa High 
DOWN KDM4B O94953 Cupid Very High 
DOWN KDM4B O94953 ElMMo3 High 
DOWN KDM4B O94953 TargetScan Very High 
DOWN KLF11 O14901 CoMeTa High 
DOWN KLF11 O14901 miRTar2GO High 
DOWN KLF11 O14901 microrna.org Very High 
DOWN KLF2 Q9Y5W3 microrna.org High 
DOWN KLHL24 Q6TFL4 ElMMo3 High 
DOWN KLHL24 Q6TFL4 MultiMiTar High 
DOWN LOX P28300 Cupid Very High 
DOWN LOX P28300 DIANA High 
DOWN LOX P28300 ElMMo3 Very High 
DOWN LOX P28300 MirTar High 
DOWN LOX P28300 Mirza-G High 
DOWN LOX P28300 TargetScan Very High 
DOWN LOX P28300 miRDB High 
DOWN LOX P28300 miRTar2GO High 
DOWN LOX P28300 MirAncesTar High 
DOWN LOX P28300 microrna.org High 
DOWN MCTP2 Q6DN12 microrna.org High 
DOWN MPP2 Q14168 MultiMiTar High 
DOWN MXI1 P50539 CoMeTa Very High 
DOWN MXI1 P50539 Cupid Very High 
DOWN MXI1 P50539 ElMMo3 Very High 
DOWN MXI1 P50539 TargetScan Very High 
DOWN MYO1H Q8N1T3 microrna.org High 
DOWN NAMPT P43490 microrna.org Very High 
DOWN NSUN3 Q9H649 CoMeTa High 
DOWN OTUD1 Q5VV17 Cupid Very High 
DOWN OTUD1 Q5VV17 ElMMo3 High 
DOWN OTUD1 Q5VV17 microrna.org High 
DOWN PCGF5 Q86SE9 MultiMiTar High 
DOWN PCGF5 Q86SE9 miRTar2GO High 
DOWN PDK1 Q15118 miRTar2GO High 
DOWN PDK1 Q15118 microrna.org High 
DOWN PER1 O15534 CoMeTa High 
DOWN PER1 O15534 Cupid Very High 
DOWN PER1 O15534 ElMMo3 Very High 
DOWN PER1 O15534 MAMI High 
DOWN PER1 O15534 MultiMiTar High 
DOWN PER1 O15534 PACCMIT High 
DOWN PER1 O15534 TargetScan Very High 
DOWN PFKL P17858 miRTar2GO High 
DOWN PFKP Q01813 microrna.org High 
DOWN PI15 O43692 CoMeTa High 
DOWN PI15 O43692 Cupid Very High 
DOWN PI15 O43692 DIANA High 
DOWN PI15 O43692 ElMMo3 Very High 
DOWN PI15 O43692 MirTar High 
DOWN PI15 O43692 Mirza-G High 
DOWN PI15 O43692 MultiMiTar High 
DOWN PI15 O43692 PACCMIT Very High 
DOWN PI15 O43692 TargetRank Very High 
DOWN PI15 O43692 TargetScan Very High 
DOWN PI15 O43692 miRTar2GO High 
DOWN PI15 O43692 MirAncesTar High 
DOWN PI15 O43692 microrna.org High 
DOWN PIK3CB P42338 TargetScan Very High 
DOWN PNRC1 Q12796 microrna.org Very High 
DOWN PRDM1 O75626 CoMeTa High 
DOWN PRDM1 O75626 Cupid Very High 
DOWN PRDM1 O75626 ElMMo3 High 
DOWN PRDM1 O75626 miRTar2GO High 
DOWN PRDM1 O75626 MirAncesTar High 
DOWN PRDM1 O75626 microrna.org High 
DOWN PRKAB2 O43741 CoMeTa High 
DOWN PRKAB2 O43741 Cupid Very High 
DOWN PRKAB2 O43741 DIANA High 
DOWN PRKAB2 O43741 ElMMo3 Very High 
DOWN PRKAB2 O43741 MirTar High 
DOWN PRKAB2 O43741 MultiMiTar High 
DOWN PRKAB2 O43741 TargetRank High 
DOWN PRKAB2 O43741 TargetScan Very High 
DOWN PRKAB2 O43741 microrna.org High 
DOWN PTTG1IP P53801 miRTar2GO High 
DOWN PXMP4 Q9Y6I8 CoMeTa High 
DOWN PXMP4 Q9Y6I8 ElMMo3 High 
DOWN PXMP4 Q9Y6I8 MultiMiTar High 
DOWN PXMP4 Q9Y6I8 TargetScan Very High 
DOWN PXMP4 Q9Y6I8 MirAncesTar High 
DOWN RAP2C Q9Y3L5 microrna.org Very High 
DOWN RHOB P62745 CoMeTa Very High 
DOWN RNF217 Q8TC41 TargetScan Very High 
DOWN RPS10 P46783 MAMI High 
DOWN RPS24 P62847 CoMeTa High 
DOWN RPS24 P62847 miRTar2GO High 
DOWN RUSC2 Q8N2Y8 miRTar2GO High 
DOWN SGK1 O00141 CoMeTa High 
DOWN SGK1 O00141 Cupid Very High 
DOWN SGK1 O00141 ElMMo3 Very High 
DOWN SGK1 O00141 MAMI High 
DOWN SGK1 O00141 MirTar High 
DOWN SGK1 O00141 Mirza-G High 
DOWN SGK1 O00141 MultiMiTar High 
DOWN SGK1 O00141 PACCMIT High 
DOWN SGK1 O00141 TargetScan Very High 
DOWN SGK1 O00141 miRDB High 
DOWN SGK1 O00141 miRTar2GO High 
DOWN SGK1 O00141 MirAncesTar High 
DOWN SGK1 O00141 microrna.org Very High 
DOWN SLC2A1 P11166 CoMeTa Very High 
DOWN SRGAP3 O43295 CoMeTa High 
DOWN SRGAP3 O43295 MultiMiTar High 
DOWN SRGAP3 O43295 MirAncesTar High 
DOWN TIPARP Q7Z3E1 CoMeTa Very High 
DOWN TNFRSF9 Q07011 CoMeTa High 
DOWN TNFRSF9 Q07011 Cupid Very High 
DOWN TNFRSF9 Q07011 DIANA High 
DOWN TNFRSF9 Q07011 MAMI High 
DOWN TNFRSF9 Q07011 TargetRank Very High 
DOWN TNFRSF9 Q07011 microrna.org Very High 
DOWN TPT1 P13693 microrna.org Very High 
DOWN TXNIP Q9H3M7 miRTar2GO High 
DOWN UPK1B O75841 CoMeTa High 
DOWN UPK1B O75841 ElMMo3 High 
DOWN UPK1B O75841 MAMI High 
DOWN UPK1B O75841 MultiMiTar High 
DOWN UPK1B O75841 PACCMIT High 
DOWN UPK1B O75841 TargetScan Very High 
DOWN UPK1B O75841 microrna.org High 
DOWN VIM P08670 CoMeTa Very High 
DOWN WISP2 O76076 miRTar2GO High 
DOWN WWC1 Q8IX03 MAMI High 
DOWN XDH P47989 ElMMo3 High 
DOWN XDH P47989 TargetRank Very High 
DOWN XDH P47989 microrna.org High 
DOWN ZC3H6 P61129 MultiMiTar High 
DOWN ZFP36 P26651 CoMeTa High 
DOWN ZFP36 P26651 Cupid Very High 
DOWN ZFP36 P26651 ElMMo3 Very High 
DOWN ZFP36 P26651 MAMI High 
DOWN ZFP36 P26651 TargetScan Very High 
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